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ABSTRACT 
Part 1 
Introduction: Phosphodiesterases (PDEs) hydrolyse cyclic nucleotides that regulate ischemia-
reperfusion injury (IRI) in the heart. Phosphodiesterases-5 (PDE5) inhibition increases cyclic 
guanosine monophosphate (cGMP) levels and thereby promotes cardioprotection. Cannabidiol is a 
cannabinoid that can alter cGMP levels and induced protection in whole hearts. Cannabidiol-mediated 
cardioprotection might be controlled by specific PDEs, possibly PDE5. 
This study aimed to: 
 Evaluate the role of PDE5 inhibition in IRI.
 Determine whether PDE5 plays a role in cannabidiol-mediated protection.
Methods: Cultured adult rat cardiomyocytes were subjected to 20 minutes ischemia, 60 minutes 
reperfusion, which included mitochondrial staining to measure mitochondrial function with JC-1, 
followed by fluorescence microscopy and image analysis. A cardioprotective dose of cannabidiol and 
time of intervention was sought by administration of cannabidiol (0.001 μM, 1 μM and 100 μM) during 
ischemia and reperfusion, only ischemia, and only reperfusion, respectively. 10 μM Sildenafil was 
administered during ischemia only to inhibit PDE5. 
Results: Ischemia-reperfusion reduced cell viability according to morphology by 79 % and 
mitochondrial function by 50 %. None of the treatments induced cardioprotection. 
Conclusion: The lack of cardioprotection from cannabidiol and sildenafil might have been due to (1) 
the ischemic conditions being too harsh, (2) the analysis program being faulty, or (3) unreliable data 
from morphology analysis. These three points of concern became the basis for the new objectives 
investigated in Part 2 of this thesis. 
Part 2 
Introduction: Cell viability and mitochondrial function are parameters normally evaluated in 
cardiomyocytes, and were also used in this study, but cardioprotection could not be found. This raised 
concerns about the reliability of the image analysis program (ImageJ), the severity of ischemia, and 
the reliability of the parameters measured. The method used to determine cell viability was especially 
questioned, because it relies on the researcher to classify rod cells as viable and round cells as dead, 
which is thus subjective. Morphometry analysis with length over width (L/W) removes the human 
aspect, allowing cell viability to be determined by classifying cardiomyocytes with L/W ≥ 1.5 as viable. 
Length on its own is also a morphometric measurement, but is seldom used. 
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Part 2 of this study aimed to: 
 Compare image analysis of ImageJ with that of CellProfiler. 
 Optimize conditions for ischemia-reperfusion and hypoxia-reperfusion. 
 Compare morphology analysis with morphometry analysis. 
Methods: The sildenafil experimental images from Part 1 were reanalyzed using CellProfiler and the 
data compared with that found with ImageJ. Ischemia-reperfusion was induced with less harsh 
conditions for 1 hour, and compared to hypoxia-reperfusion, using cell viability and mitochondrial 
function. Cell viability was determined by selecting viable cells by rod shape, compared to L/W ≥ 1.5, 
and length ≥ 55 μm. The average length for hypercontracted cells in the normoxic population was 
determined, and found to be consistently below 55 μm. Length ≥ 55 μm was chosen as morphometry 
selection to identify viable cells. 
Results: Both ImageJ and CellProfiler provided similar data. Cell viability for L/W ≥ 1.5 and 
length ≥ 55 μm were similar, but higher than morphology, especially for hypoxia-reperfusion, but not 
for ischemia-reperfusion. L/W ≥ 1.5 and length ≥ 55 μm found differences between normoxia and 
hypoxia-reperfusion, unlike morphology. The differences can be explained by morphology selecting 
fewer cells that are perfectly healthy, while morphometry selects more cells with varying degrees of 
cell injury. Only for ischemia-reperfusion did all parameters provide similar knockdown. This can be 
explained by ischemia-reperfusion that induced severe injury and hypoxia-reperfusion that induced 
less injury. 
Conclusion: The lack of cardioprotection by PDE5 inhibition and cannabidiol was not due to an image 
analysis error by the program, but might rather be due to ischemia-reperfusion that was too harsh. 
Conversely, hypoxia-reperfusion induced injury that was not harsh enough. Morphometry selection is 
biased and unreliable, and morphometry selection should rather be used to evaluate an injured 
cardiomyocyte population.  
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OPSOMMING 
Deel 1 
Inleiding: Fosfodiesterases (FDEs) hidroliseer sikliese nukleotiedes wat iskemie-herperfusie besering 
(IRB) in die hart reguleer. Fosfodiesterases-5 (FDE5) inhibisie verhoog sikliese guanosien 
monofosfaat (sGMF) vlakke en bevorder daardeur kardiobeskerming. Cannabidiol is ‘n cannabinoïde 
wat sGMF vlakke kan verander en induseer beskerming in heel harte. Cannabidiol-bemiddelde 
kardiobeskerming word moontlik beheer deur spesifieke FDEs, waarskynlik FDE5. 
Die doelwitte van hierdie studie was om: 
 Die rol van FDE5 inhibisie in IRB te evalueer. 
 Te bepaal of FDE5 ‘n rol speel in cannabidiol-bemiddelde beskerming. 
Metodes: Gekultuurde volwasse rotkardiomiosiete was onderwerp aan 20 minute iskemie, 60 minute 
herperfusie, insluitend mitokondriale kleuring om mitokondriale funksie te meet met JC-1, gevolg deur 
fluoressensie mikroskopie asook beeldanalise. ‘n Kardiobeskermende dosis van cannabidiol en 
intervensietyd was bepaal deur die administrasie van cannabidiol (0.001 μM, 1 μM en 100 μM) 
gedurende iskemie en herperfusie, slegs iskemie, en slegs herperfusie, afsonderlik. 10 μM Sildenafil 
was geadministreer gedurende iskemie alleenlik om FDE5 te inhibeer. 
Resultate: Iskemie-herperfusie het sellewensvatbaarheid volgens morfologie met 79 % en 
mitokondriale funksie met 50 % verminder. Geen van die behandelinge het kardiobeskerming 
geïnduseer nie. 
Gevolgtrekking: Die gebrek aan kardiobeskerming van cannabidiol en sildenafil is moonlik as gevolg 
van (1) die iskemie kondisies was te skadelik, (2) die analise program was foutief, of (3) die data van 
morfologie analise was onbetroubaar. Hierdie drie punte van kommer het die basis geword vir die 
nuwe objektiewe geëvalueer in Deel 2 van hierdie tesis. 
Deel 2 
Inleiding: Sellewensvatbaarheid en mitokondriale funksie is die parameters wat normaalweg 
geëvalueer word in kardiomiosiete. Hierdie studie het ook die parameters gebruik, maar 
kardiobeskerming kon nie gevind word nie. Dit het onsekerheid veroorsaak oor die betroubaarheid van 
die beeldanalise program (ImageJ), die intensiteit van iskemie, en die betroubaarheid van die 
geëvalueerde parameters. Die metode wat gebruik was om sellewensvatbaarheid te bepaal was veral 
bevraagteken, want dit is afhanklik van die navorser om staaf-vormige selle as lewendig en ronde 
selle as dood te klassifiseer, en is dus subjektief. Morfometrie analise met lengte oor wydte (L/W) 
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verwyder die menslike aspek, en laat toe dat sellewensvatbaarheid bepaal word deur kardiomiosiete 
met L/W ≥ 1.5 as lewendig te klassifiseer. Lengte op sy eie is ook ‘n morfometrie meting, maar word 
selde gebruik. 
Die doel van Deel 2 van hierdie studie was om: 
 Beeldanalise van ImageJ met die van CellProfiler te vergelyk. 
 Die kondisies vir iskemie-herperfusie en hipoksie-herperfusie te optimaliseer. 
 Morfologie analise met morfometrie analise te vergelyk. 
Metodes: Die sildenafil eksperimentele beelde van Deel 1 is geherevalueer met CellProfiler en die 
data is vergelyk met die data gevind met ImageJ. Iskemie-herperfusie was geïnduseer met minder 
skadelike kondisies vir 1 uur, en was toe vergelyk met hipoksie-herperfusie, asook met die gebruik 
van sellewensvatbaarheid en mitokondriale funksie. Sellewensvatbaarheid was bepaal deur lewendige 
selle met staaf vorm te kies, en is toe vergelyk met L/W ≥ 1.5, en lengte ≥ 55 μm. Die gemiddelde 
lengte vir hiper-gekontrakteerde selle in die normoksiese populasie was bepaal, en is gevind om 
konstant onder 55 μm te wees. Lengte was gekies as morfometriese seleksie ten einde lewendige 
selle te identifiseer. 
Resultate: Beide ImageJ en CellProfiler het dieselfde data gehad. Sellewensvatbaarheid vir L/W ≥ 1.5 
en lengte ≥ 55 μm was ooreenstemmend, maar hoër as morfologie, spesifiek vir hipoksie-herperfusie, 
maar nie vir iskemie-herperfusie nie. L/W ≥ 1.5 en lengte ≥ 55 μm het verskille tussen normoksie en 
hipoksie-herperfusie gevind, anders as morfologie. Die verskille kan verduidelik word deur morfologie 
wat minder selle selekteer wat net perfek gesond is, terwyl morfometrie selle selekteer wat 
verskillende grade van selskade toon. Slegs vir iskemie-herperfusie het alle parameters dieselfde 
besering getoon. Dit kan verduidelik word deur iskemie-herperfusie wat intense skade induseer en 
hipoksie-herperfusie wat gevolglik minder skade induseer. 
Gevolgtrekking: Die tekort aan kardiobeskerming deur FDE5 inhibisie en cannabidiol was nie as 
gevolg van ‘n beeldanalise fout deur die program nie, maar moontlik eerder weens 
iskemie-herperfusie wat te skadelik was. Inteenstelling, hipoksie-herperfusie het skade geïnduseer 
wat nie skadelik genoeg was nie. Morfologie seleksie is bevooroordelend en onbetroubaar, en 
morfometrie seleksie moet eerder gebruik word om ‘n beseerde kardiomiosiet populasie te evalueer. 
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  CHAPTER 1
Literature Review 
1.1 Acute myocardial infarction 
The World Health Organization (WHO) statistics indicate that, of the 56 million global deaths in 2012, 
non-communicable diseases contributed 68 % (Finegold et al., 2013). The leading non-communicable 
disease (NCD) is cardiovascular diseases, of which coronary heart disease (CHD) is most prevalent, 
contributing 17.5 million deaths. CHD is predicted to be close on the heels of human 
immunodeficiency virus (HIV) to become the leading cause of death and disability worldwide 
(Finegold et al., 2013). 
CHD is prevalent amongst diabetic, hypertensive and heart failure patients. Alternative risk factors 
include genetic predisposition, smoking, unhealthy dietary habits, or sedentary lifestyle 
(Boersma et al., 2003). Vascular pathologies associated with these diseases and the risk factors 
mentioned can trigger ischemia, which leads to acute myocardial infarction (AMI) also known as a 
heart attack (Hausenloy & Yellon, 2013). 
1.2 Pathology associated with acute myocardial ischemia (summarized in Figure 1.1) 
Acute myocardial ischemia is prompted by a coronary occlusion, depriving the cardiomyocytes of 
oxygen, nutrients and energy (Reimer & Ideker, 1987), and is reflected by cardiomyocyte death. The 
deprivation of oxygen prevents oxidative phosphorylation in the mitochondria, leading to membrane 
depolarization, energy (adenosine triphosphate (ATP)) depletion and inhibition of cardiomyocyte 
contraction (Hausenloy & Yellon, 2013). 
The heart attempts to compensate for the ATP loss by switching the cellular metabolism to anaerobic 
glycolysis. However, anaerobic glycolysis can only produce a very limited amount of ATP at a very 
slow rate, but with the addition of lactate accumulation, which contributes to the reduction of 
intracellular pH (to < 7.0) (Dennis et al., 1991; Hausenloy & Yellon, 2013). Anaerobic glycolysis and 
other ATP-dependent processes rapidly hydrolyse ATP, and thereby release hydrogen (H+), which 
mainly contributes to acidosis (Dennis et al., 1991; Murphy & Steenbergen, 2008). 
The intracellular protons generated during ischemia are removed by the sodium-hydrogen (Na+-H+) 
exchanger, which exchanges intracellular protons for Na+ entry. Low ATP levels retard Na+ removal by 
the ATP-dependent sodium-potassium (3Na+-2K+) ATPase, aggravating the accumulation of Na+ in 
the cell in response to the effect of the Na+-H+ exchanger. 
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The cell, overloaded with Na+, activates the sodium-calcium (2Na+-Ca2+) ion exchanger in reverse 
mode (Avkiran & Marber, 2002). Under normal conditions the 2Na+-Ca2+ ion exchanger extrudes Ca2+ 
from the cell by indirectly using the ATP of the Na+ gradient set by the 3Na+-2K+ ATPase. During 
ischemia, Na+ overload reduces the inwardly directed Na+ gradient, allowing Ca2+ to rise via 2Na+-Ca2+ 
ion exchanger, in effect increasing Ca2+ levels within the cell (Imahashi et al., 2005). 
Acidosis and alterations in the ion transport system, as a result from prolonged ischemia, can inhibit 
cardiomyocyte contraction and relaxation (Buja, 2005; Hausenloy & Yellon, 2013). Insufficient ATP 
supply prevents actin-myosin cross bridge dissociation and the restoration of resting cytosolic Ca2+ 
levels, which initiates contracture (Buja et al., 1988). 
Ultimately, the various ischemic stress signals activate death pathways, apoptosis or necrosis. Cell 
death via necrosis is triggered by acute cellular injury, compared to programmed cell death via 
apoptosis. Apoptosis is triggered by the cell sensing stress within itself (intrinsic pathway) and 
receiving signals from adjacent cells (extrinsic pathway) (Buja, 2005). 
1.3 Pathology associated with reperfusion (summarized in Figure 1.1) 
Resupplying the heart with blood and thus oxygen (reperfusion) is critical and the common method 
used to preserve heart tissue viability. This increase in oxygen delivery can be rapid and forms 
reactive oxygen species (ROS) (Kilgore & Lucchesi, 1993) that conversely induce damage. The extent 
of damage depends on the duration of ischemia. If ischemia is prolonged, reperfusion leads to 
irreversible damage - reperfusion injury, first put forth in 1977 by Hearse. 
Reperfusion is characterized by a rapid increase in intracellular free Ca2+ concentration 
(Kilgore & Lucchesi, 1993). The rise in Ca2+ is mainly due to a concentration gradient, which permits 
the cell to exchange Na+ for Ca2+ via Na+-Ca2+ exchanger (Fehrer et al., 1980). If intracellular Ca2+ 
levels are above normal, cell death is activated (Murphy & Steenbergen, 2008). 
Ca2+ influx initiates biochemical events, including enzyme activation and ultrastructural changes. 
Different groups of intracellular enzymes are activated: phospholipases, proteases and calpains. 
Phospholipases are mostly responsible for ATP depletion, by using ATP to hydrolyse fatty acids, 
preventing enough ATP to accumulate for the cardiomyocyte to survive (Becker & Ambrosio, 1987). 
Proteases, specifically calcium-activated neutral protease (CANP), mediate myofibrillar turnover and 
degrade various structural proteins, including cytoskeletal filaments, needed to maintain the rigid 
cardiomyocyte structure (Dayton et al., 1976). Calpain enzymes are involved in initiating 
cardiomyocyte death via activation of apoptosis and necrosis (Murphy & Steenbergen, 2008). 
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The ultrastructural changes include contracture bands development and the formation of large 
amorphous solidities within mitochondria (Kilgore & Lucchesi, 1993). 
It is not just the Ca2+ levels that render the cardiomyocytes dead. During re-oxygenation there is a 
rapid ATP production recovery, which together with the Ca2+ overload reactivates the contractile 
machinery and leads to an uncontrolled Ca2+-dependent contracture (Piper et al., 2003). Contracture 
is a condition of cardiomyocyte shortening, which renders the cardiomyocyte resistant to stretching. 
The low intracellular pH from ischemia is restored by the washout of lactate and the activation of the 
Na+-H+ exchanger. The pH shift towards alkalinity causes continuation of cardiomyocyte contracture to 
a more severe degree – hypercontracture (Hausenloy & Yellon, 2013). 
Oxidative stress, intracellular Ca2+ (ICa2+) influx, phosphate overload, ATP depletion and the rapid shift 
in pH permits the opening of the mitochondrial permeability transition pore (mPTP). The mPTP is a 
non-selective channel of the inner mitochondrial membrane. This channel commonly remains closed 
during ischemia while the Ca2+ increase alone has no effect. When open, the mPTP results in 
mitochondrial membrane depolarization and oxidative phosphorylation uncoupling, leading to further 
ATP depletion and finally cell death (Hausenloy & Yellon, 2003). 
Ischemic and reperfusion levels of Ca2+, ATP, pH, the activation of necrosis and apoptosis, and 
changes in cell morphology and cell length, serve as indicative markers for protection versus damage 
signaling. 
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Figure 1.1 Pathology associated with acute myocardial ischemia and reperfusion. This figure is modified from 
(Hausenloy & Yellon, 2013). Acute myocardial ischemia is prompted by a coronary occlusion. The deprivation of 
oxygen prevents oxidative phosphorylation and the heart switches to anaerobic glycolysis, which causes lactate 
to accumulate and the intracellular pH to reduce. The low pH induces the Na
+
-H
+
 exchanger to extrude H
+
, 
resulting in intracellular Na
+
 overload, which activates the 2Na
+
-Ca
2+
 exchanger to function in reverse to extrude 
Na
+ 
for Ca
2+
 and consequently causes intracellular Ca
2+
 overload. The Low ATP levels retard Na
+
 removal by the 
3Na
+
-2K
+
 ATPase, aggravating the accumulation of Na
+
 in the cell in response to the effect of the Na
+
-H
+
 
exchanger. The acidic pH condition during ischemia inhibits the opening of the mPTP and inhibits cardiomyocyte 
contracture. During reperfusion the increase in oxygen delivery can be rapid and forms ROS, which results in the 
opening of the mPTP. Reperfusion reactivates the Na+-H+ exchanger and leads to the washout of lactate, which 
rapidly restores the intracellular pH and ultimately stimulates the opening of the mPTP and activates 
hypercontracture. Reperfusion is characterized by a rapid increase in intracellular free Ca
2+
 concentration mainly 
due to a concentration gradient, which permits the cell to exchange Na
+
 for Ca
2+
 via Na
+
-Ca
2+
 exchanger. If 
intracellular Ca
2+
 levels are above normal the mPTP opens and hypercontracture is activated, which leads to 
reperfusion injury and finally cell death. 
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1.4 Conditioning as protective intervention 
Conditioning is the process of giving a stimulus and then taking the stimulus away to stimulate 
cardioprotection. Cardiac conditioning can be done either before (pre), during (per), or after (post) 
ischemia (Bell & Yellon, 2012). Although protection from preconditioning seems to be most effective 
(Xin et al., 2010), the onset of ischemia can only be predicted in a few instances, for example in 
surgery, and therefore per- and post- conditioning is clinically more relevant. 
It is possible to condition the heart directly, or via distal tissues (remote conditioning). Conditioning 
activates endogenous cytoprotective pathways, which stimulate protection against 
ischemia-reperfusion (I/R) injury in the heart and cardiomyocytes (Bell & Yellon, 2012). 
Protection by conditioning mainly involves the activation of the reperfusion injury salvage kinase 
(RISK) pathway. RISK pathway activation signals via phosphatidylinositol 3-kinase (PI3K) and the 
mitogen-activated protein kinase p44/p42 (MEK1/2), which activates extracellular signal-regulated 
kinase (ERK1/2). Both these pathways exert a critical role in stimulating protection (Xin et al., 2010). 
Alternatively, conditioning can activate the release of autacoids, such as adenosine, opioids, and 
bradykinin, which are chemical transmitter substances that act as local hormones 
(Downey & Cohen, 2006). 
Autacoids are periodically released to handle several biological actions including modulating the 
activity of smooth muscles, platelets, glands, nerves and other tissues (Roy, 2007). Autacoids serve 
as agonists for beta-adrenoreceptors (β-ARs) coupling to inhibitory G-protein (Gi). Once activated, Gi 
activates calcium-activated serine-threonine kinase (PKC) and it is by this mechanism that protection 
is largely governed. The precise mechanism that leads to protection is still elusive 
(Downey & Cohen, 2006). 
Conditioning, and the cardioprotective effect thereof, can be mimicked by drug treatment 
(Hausenloy & Yellon, 2011). Unlike conditioning, drug treatment involves giving a stimulus 
continuously, without removing the stimulus. 
1.5 The isolated cardiomyocyte model 
Cardiomyocytes account for approximately 60 % of the cells in the heart, and under normal conditions 
they allow continuous rhythmic contraction and relaxation for heart pump function 
(Maurice et al., 2003). Cardiomyocytes express a wide range of surface receptors, including G-protein 
coupled receptors (GPCRs) and receptor tyrosine kinases (RTKs). These cells can be isolated, 
cultured, and used for experimental purposes. 
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The isolated cardiomyocyte model gives great insight into single, or a cascade of, intracellular 
signaling candidates: for example visualizing Ca2+ flux, protein interactions, and cell mechanics 
(Louch et al., 2011). This is done in the absence of hormonal homeostasis and complex neural control 
(Kabaeva et al., 2008). The whole heart model does not allow for this attribute due to the influence of 
vasculature and other cells (Bell & Yellon, 2012). 
Cultured cardiomyocytes can be used in various experimental settings: cell contractility assessment, 
cell viability, and cell-signaling studies. 
There are two primary culture models - neonatal and adult cardiomyocytes. Neonatal cardiomyocytes, 
harvested from rats aged 1 - 3 days, are un-differentiated cells and thus provides a simpler 
experimental system. Compared to adult cardiomyocytes harvested from rats aged 7 - 8 weeks, 
neonatal cardiomyocytes are suitable candidates for non-viral gene transfer and have the advantage 
of being easily cultured and for longer time periods (Louch et al., 2011). Isolation of neonatal 
cardiomyocytes does not require the tedious procedure of aorta cannulation and perfusion, necessary 
to yield adult cardiomyocytes. 
Yet, neonatal cells attach slower (24 h) to culturing adhesives than adult cardiomyocytes (1 - 4 h). 
Adult cardiomyocytes are mainly preferred because they are differentiated rod-shaped cells 
(Louch et al., 2011). Neonatal cells express genes differently and may not represent a good model for 
I/R, whereas the intracellular signaling in adult cardiomyocytes is more intricate and can serve as a 
better physiological comparison to human cardiomyocytes. 
Some aspects of the adult cardiomyocytes isolation model remain a challenge, first to successfully 
isolate a high quality myocyte population with ≥ 80 % viability, and secondly the maintenance of these 
cells in culture without the loss of structure and function. Various factors influence the success of the 
isolation, including the weight and age of the rats, potency of enzymes used to digest the heart, 
effectiveness of products used and human error. 
Immortalized cardiac cell lines, such as h9c2 cells, are commercially available. However, acutely 
isolated cardiomyocytes are physiologically more relevant to the living organism (Louch et al., 2011). 
1.6 Signaling pathways that promote ischemic damage or protection 
1.6.1  β-ARs signaling 
β-ARs (β1, β2, and β3) contribute significantly to the sympathetic nervous system control of heart 
function and enhancing cardiac performance to stress, exercise and injury (Lohse et al., 2003). β-ARs 
control heart function by mediating the physiological effects of catecholamines (Gao et al., 2014). 
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These receptors are expressed on the surface of cardiomyocytes, β1-AR being the most abundant 
subtype accounting for ≈ 80 % of β-AR (Communal et al., 1999) and the most active during ischemia. 
In the setting of acute myocardial ischemia, β1-AR activation, from endogenous catecholamine 
released by sympathetic nervous stimulation, induces damage (Spear et al., 2007). 
β–ARs, especially β1 and β2, regulate excitation-contraction coupling via stimulatory G-protein (Gs) 
coupling to adenylyl cyclase (AC) (Gao et al., 2014) (Figure 1.2). Activation thereof under acute 
myocardial ischemic conditions can induce apoptosis and necrosis. This is done by a mechanism 
dependent on the increase of cyclic adenosine monophosphate (cAMP) (described in section 1.7), 
which activates cAMP-dependent protein kinase (PKA) (Communal et al., 1999), finally increasing 
contraction and damage. Alternatively, β2-AR can couple to pathways independent of cAMP and Gs, 
by signaling via Gi (Xiao et al., 1999) (Figure 1.2). β2-AR coupling to Gi successfully attenuates acute 
myocardial ischemic cAMP/PKA activity, initiating cardioprotection (Communal et al., 1999). 
A cultured isolated cardiomyocyte study by Communal and colleagues (1999) found that, β-AR 
stimulation with a non-selective agonist (norepinephrine) mediates two opposing effects on apoptosis, 
where activation of β1-ARs stimulated apoptosis while activation of β2-ARs inhibited apoptosis. They 
also found that β2-AR stimulation inhibited β-AR-stimulated apoptosis, possibly via Gi. But, a decrease 
in β-AR-stimulated cAMP was not found, and they concluded that the Gi protection is possibly 
regulated by a cAMP-independent mechanism (Communal et al., 1999). It is possible that the change 
in cAMP, instead of the overall cAMP concentration, occurred in cAMP compartmentation, which they 
did not mention. They did not test for cyclic guanosine monophosphate (cGMP), and therefore it is 
also possible that the effects could have been via cGMP and cGMP-dependent protein kinase (PKG) 
signaling. The protective pathway activated from Gi coupling includes PI3K activation, activating its 
downstream target serine/threonine-specific protein kinase (PKB, also known as Akt) 
(Chesley et al., 2000; Gao et al., 2014). 
β3-AR is the rarest subtype, but expression can increase, divergent to β1-AR and β2-AR, with 
pathophysiological conditions such as heart failure and hypertrophy (Watts et al., 2013). High levels of 
catecholamines, for example released during acute myocardial ischemia, or the administration of a 
β3-AR agonist, can stimulate β3-AR. β3-AR activation results in negative inotropic effect that opposes 
positive inotropic effects by β1-AR and β2-AR and promotes protection (Figure 1.2) 
(Isidori et al., 2015). This protection is mediated by Gi coupling to nitric oxide synthase-nitric oxide 
(NOS-NO), increasing cGMP levels, and activating PKG (Watts et al., 2013). This pathway might have 
been involved in the Communal paper (1999) described in the previous paragraph. PKG ultimately 
inhibits contraction and allows relaxation (Gauthier et al., 1998). 
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Despite the constant hyper-sympathetic activity from ischemia, the stimulated response is maintained 
by β3-AR lacking PKA phosphorylation sites (Watts et al., 2013). The protective signal from β3-AR 
can only be stopped once catecholamines release recedes. β1-AR and β2-AR have PKA 
phosphorylation sites that induce receptor desensitization: blunting receptor activation and the signal 
effect. 
In isolated cardiomyocyte models β–AR agonists are used to activate β–ARs non-selectively 
(isoproterenol (Maurice et al., 2003; Yu et al., 2008)) to mimic damage (β1-AR: dobutamine 
(Chesley et al., 2000; Ufer & Germack, 2009)), and to promote protection (β2-AR: formoterol 
(Watson et al., 2013; Wills et al., 2012) and β3-AR: BRL-37433 (Gauthier et al., 1998; 
Niu et al., 2012)). 
 
Figure 1.2 Proposed diagram whereby β-AR signaling governs damage versus protection during acute 
myocardial ischemia. During ischemia neuronal synapses are stimulated to release catecholamine, which 
stimulates β1-AR (agonist: dobutamine) coupling to Gs. Gs activates AC, increasing cAMP levels, which activates 
PKA and leads to contraction (damage). Alternatively, Gs initiates apoptosis by increasing the ICa
2+
. β2-AR 
activation (by conditioning or agonist: formoterol) signals via Gs and/or Gi. Gi coupling activates PI3K, which 
activates PKB/Akt and inhibits apoptosis, promoting protection. β3-AR activation (by conditioning or agonist: 
BRL-37433) signals via Gi to increase nitric oxide (NO) levels, increasing cGMP and activates PKG. PKG activity 
blunts contraction and promotes ischemic cardioprotection. Isoproterenol is a non-selective agonist for β-ARs. 
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1.6.2  Cannabinoid signaling 
Cannabinoid (CB) receptors, CB1 and CB2, cloned in 1990 and 1993 respectively 
(Howlett et al., 2002) form part of the GPCR family and are expressed in cardiomyocytes 
(Lamontagne et al., 2006; Walsh et al., 2010). Compared to CB1, CB2 is expressed in lower levels, 
but expression is up-regulated in response to conditions such as inflammation or tissue injury to 
promote protection (Steffens & Pacher, 2012). CB receptors control physiopathological functions in the 
cardiovascular system (Mendizabal & Adler-Graschinsky, 2007), but play a minor regulatory role under 
normal physiological conditions (Wagner et al., 1998). 
Once activated, CB receptors mainly regulate heart rate and blood pressure (Hillard, 2000; 
Pacher et al., 2005; Wagner et al., 1998), where CB1 activation stimulates hypotension and 
bradycardia (Bonz et al., 2003; Gebremedhin et al., 1999; Wagner et al., 1998). 
CB receptors are mainly characterized in other systems, not in cardiomyocytes. The activation of 
these receptors signal via the Gi pathway (Wagner et al., 1998). Gi inhibits AC, and thus cAMP 
production, which reduces PKA phosphorylation (Howlett et al., 2002), and it activates the 
mitogen-activated protein kinases (MEKs)-mediated cascade (Hillard, 2000; Wagner et al., 1998). 
CB1 activation, in contrast to CB2, modulates ion channel functioning (Steffens & Pacher, 2012). CB1 
signals through Gi to inhibit L-type Ca
2+ channel currents and increase intracellular free Ca2+ 
(Gebremedhin et al., 1999). This is via Gi activating phospholipase C (PLC), which stimulates the 
release of inositol-1,4,5-triphosphate (IP3), finally initiating vasodilation in vascular smooth muscle 
cells (VSMC) (Howlett et al., 2002). The Ca2+ response mediated by CB2 is less pronounced 
(Steffens & Pacher, 2012). Similar to CB1, CB2 activation cause Ca2+ release from endoplasmic 
reticulum stores and L-type Ca2+ channel, but without channel inhibition (Zoratti et al., 2003). 
Interestingly, in neuronal cells the activation of CB1 with the agonist CP55940 stimulate NO 
production, leading to Gi activation and enhanced neuronal nitric oxide synthase (NOS) activity, which 
produce cGMP (Carney et al., 2009). In cultured cardiomyocytes the activation of CB2 with 
delta-9-tetrahydrocannabinol (THC) induces NO production and leads to an increase in cGMP 
(Shmist et al., 2006). Thus, it seems that CB1 and CB2 are both capable of inducing NO production, 
which leads to an increase in cGMP. 
In the absence of functional Gi coupling, Glass and Felder (1997) found that CB1 can activate Gs, 
which increases cAMP and PKA phosphorylation. CB1 is usually associated with inter-leukin (IL) -3, 
but when there is a double mutation in the amino-acid structure (Leucine-Alanine) of IL3, the helical 
domain makes into a single turn, and converts coupling of the receptor from Gi to Gs 
(Abadji et al., 1999). 
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Rhee and colleagues (1998) stated that the outcome of CB receptor stimulation is mainly determined 
by the AC isoforms expressed in the cell. Cells that express CB1 and CB2 receptors with 
co-expression of AC isoforms 1, 3, 5, 6, 8 or 9 inhibits cAMP accumulation, whereas AC isoforms 2, 4 
or 7 stimulates cAMP accumulation (Rhee et al., 1998). The distribution of AC isoform in heart tissue 
was described in a review article (Hanoune & Defer, 2001), where isoforms 2, 3, 4, 7, 8 are distributed 
at low levels and 5, 6, 9 at high levels. 
The activation of CB receptors with endogenous cannabinoids stimulates protection against 
myocardial ischemia and can preserve coronary endothelial function (Krylatov et al., 2001; 
Lasukova et al., 2008; Ugdyzhekova et al., 2001). Specific CB1 and CB2 blockers inhibit 
cardioprotection, indicating that the protective signal is receptor-mediated (Krylatov et al., 2001; 
Ugdyzhekova et al., 2001). 
CB receptors can also respond to phyto (plant derived)- and synthetic cannabinoids 
(Walsh et al., 2010). The psychoactive THC and the non-psychoactive (-)-cannabidiol (CBD) are 
derived from the plant Cannabis sativa (Howlett et al., 2002; Lasukova et al., 2008) and serve as 
pharmacological active agents (Zoller et al., 2000). THC and CBD are the two most abundant 
compounds, out of the seventy active compounds, in Cannabis sativa (Walsh et al., 2010). 
CBD, which structure is illustrated by Figure 1.3, is an agonist for CB1 and CB2 receptors – even at 
low concentrations: 1 μM – 10 μM (Thomas et al., 2007; Pertwee, 2008). 
 
 
Figure 1.3 The structure of CBD (Mechoulam et al., 2007). 
 
The precise pharmacological action of CBD is yet to be clarified. A review by Mechoulam and 
colleagues (2007) described the effects of CBD that mediate cardioprotection, including anti-necrotic, 
antioxidant, and anti-inflammatory. CBD has the ability to interfere with key pathological events during 
I/R, such as ion channel opening (Mamas & Terrar, 1998) and platelet activation 
(Formukong et al., 1989). 
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A study by Durst and colleagues (2007) tested the in vivo and ex vivo effects of CBD administration on 
I/R. In vivo, where rats received CBD 1 h before ischemia induction, and then again every 24 h for 7 
days after ischemia, resulted in a decrease in infarct size, associated with reduced myocardial 
inflammation, and reduced IL-6 levels. Ex vivo, where rats received CBD 24 or 1 h before they were 
sacrificed, the isolated hearts showed no significant difference in the infarct size or left ventricular 
pressure development during I/R. They concluded that in vivo, but not ex vivo, CBD induces a 
significant cardioprotective effect against ischemia (Durst et al., 2007). 
In 2010, Walsh and colleagues demonstrated that in vivo acute administration of CBD on rat hearts, 
either 10 min prior to 30 min of ischemia, or 10 min prior to 2 h of reperfusion, is cardioprotective by 
reducing both ventricular arrhythmias and infarct size. Thus, in whole hearts the acute CBD 
administration stimulates cardioprotection. 
A doctoral thesis done by Hepburn (2014), firstly in vivo, investigated the receptors involved in the 
anti-arrhythmic effect of CBD in a coronary artery occlusion rat model. This is based on the ability of 
CBD to also activate the receptor G protein-coupled receptor 55 (GPR55) (Hepburn, 2014). CBD 
administration in vivo caused a hypotensive response, induced vasodepressor response, and reduced 
arrhythmias, which was potentiated when GPR55 was co-activated with the agonist AM251. This 
indicates the possible cross-talk between CB receptors and GPR55 to reduce the incidence of 
arrhythmias (Hepburn, 2014). Secondly, the in vitro experiments of the study determined if CBD alters 
ICa2+ in isolated cardiomyocytes, and found that CBD cannot modulate ICa2+ in cardiomyocytes. 
In 2015 Feng and colleagues tested the therapeutic effects of CBD on I/R injury in rabbits, where 90 
min coronary artery occlusion was induced, followed by 2 intravenous CBD doses before 24 h 
reperfusion. CBD reduced the infarct size and facilitated the restoration of left ventricular function. 
Only these few studies have tested the role of CBD in the setting of I/R, where the whole heart was 
evaluated, but no work has been done on isolated cardiomyocytes. Although it seems that the in vivo 
anti-inflammatory response from CBD provides protection, we propose that another protective signal is 
involved. Given that CB receptors couple to Gi we expect that CB activation will suppress cAMP levels 
and lead to an increase in cGMP, which initiates cardioprotection via PKG (see section 1.7). Other 
cannabinoids have been shown to stimulate cardioprotection in vivo and in vitro. 
The activation of CB2 in vivo, with synthetic cannabinoid HU-210 (Krylatov et al., 2001) or the 
non-selective agonist WIN55212-2 (Di Filippo et al., 2004) before I/R, reduced the infarct size and 
ventricular arrhythmias. 
In an in vivo mouse heart I/R study, CB2 was activated with the selective JWH-133 agonist 5 min 
before reperfusion (Montecucco et al., 2009). The results indicated a reduction in infarct size, which 
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was associated with a decrease in oxidative stress and neutrophil infiltration via activation of ERK1/2 
and signal transducer and activator of transcription-3 (STAT-3). The researchers concluded that CB2 
activation reduces the infarct size by a direct cardioprotective mechanism on cardiomyocytes and 
neutrophils (Montecucco et al., 2009). 
An in vitro study (Shmist et al., 2006) tested the effect that pre-treatment with THC exerts on CB1 and 
CB2 in cultured neonatal cardiomyocytes, subjected to 60, 90 and 120 min hypoxia. They found that 
THC activating CB2, and not CB1, induces NO production and possibly “pre-trains” the 
cardiomyocytes to hypoxic conditions (Shmist et al., 2006). 
It seems that the protection induced in myocardial ischemia from CB receptor activation is mainly 
mediated by CB2 activation, and not CB1 (Lamontagne et al., 2006). 
Whole heart experiments prove that the administration of CBD can protect the heart from I/R damage 
(Durst et al., 2007; Hepburn, 2014; Mechoulam et al., 2007; Walsh et al., 2010), possibly by activating 
both CB1 and CB2 to modulate cyclic nucleotide (CN) levels via Gi coupling, or for CB1 via Gs. The 
lack of experiments that focus on the role of acute CBD administration in isolated cardiomyocytes in 
the setting of acute myocardial ischemia needs to be addressed. This study will evaluate the effect of 
CBD when administrated at the start of ischemia and continuously during I/R. 
1.7 CN mediated signaling during I/R 
CNs (cAMP and cGMP) are tightly regulated second messengers. They are critically involved in 
various intracellular processes (Dayton et al., 1976; Leineweber et al., 2006). Under normal conditions 
rhythmic contraction of the heart is maintained by cAMP and cGMP levels. 
cAMP is synthesized from ATP by AC in response to G-protein activation by β-AR. cAMP production 
activates PKA and thereby enhance cardiac output through an integrated effect of increased 
contraction, relaxation and heart rate (Ishikawa & Homcy, 1997). Removal of the agonist from the 
β-AR rapidly reverses this effect, deactivates PKA and cAMP is degraded by phosphodiesterases 
(PDEs). 
In pathophysiological conditions such as acute myocardial ischemia, catecholamine release and thus 
signaling is maintained, which in this case is released in response to the ischemic insult. β-AR 
signaling is therefore maintained, with the receptor desensitizing only after an elongated period. The 
resultant increase in cAMP during ischemia is detrimental, it leads to sustained and increased cardiac 
contraction, ATP depletion, tissue damage and cell death. Furthermore, Ishikawa and Homcy (1997) 
proposed that during ischemia, PKC regulates cardiac AC. The activity of PKC is sustained by the 
influx of Ca2+ during ischemia (described in section 1.2), and contributes to ischemic damage. 
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cGMP is the second messenger activated by NO and atrial natriuretic peptide (ANP), but unlike cAMP 
it is associated with cardioprotection (Dodge-Kafka et al., 2006). ANP couples natriuretic peptide 
receptor-A (NPR1/NPRA/ANPA), which is a GPCR, to guanylyl cyclase (GC), and converts guanosine 
triphosphate (GTP) to cGMP. cGMP then stimulates PKG which initiates cardiomyocyte relaxation 
(Cawley et al., 2007). 
cGMP elevation is associated with a negative inotropic effect that initiates protection against I/R injury 
and prevents apoptosis (Francis, 2010). PKG activated by cGMP lowers ICa2+ and thereby reduces 
contraction. Moreover, an elevation in cGMP can suppress β-AR damage signaling via PKG activity 
(Francis, 2010). 
1.8 Compartmentation of cAMP and cGMP 
cAMP and cGMP subcellular localization is critical in controlling the physiological effects, amplitude, 
and specificity of a signal. Specific localizations are known as compartments and serve as defined 
microenvironments (Fischmeister et al., 2006). 
The assembled compartments comprise of unique cyclases, degradation enzymes (PDEs) and 
kinases that are attached to anchoring proteins (scaffolds), which bind to specific membrane 
molecules (Miller & Yan, 2010). 
Anchoring proteins are therefore molecular configurations of micro-domains, which increase the 
efficacy and speed of signal transduction (Fischmeister et al., 2006). Recent CN studies revealed that 
compartmentation of certain signaling molecules independently regulate the signal for each 
physiological event (Omori & Kotera, 2007). 
Compartments allow rapid and preferential modulation of cAMP and cGMP production 
(Fischmeister et al., 2006). Importantly, some cAMP compartments in the heart appear to be close to 
the sarcolemma, adjacent to β-ARs and under the control of specific regulating enzymes 
(Mongillo et al., 2006). Further action of cAMP localization is attributed to PKA pools, and their 
association with PKA-anchoring proteins (Dodge-Kafka et al., 2006). 
Evidence for distinct cellular cGMP compartmentalization in the sub-sarcolemma and the cytosol are 
provided by several researchers (Castro et al., 2010; Maurice at al., 2003; McConnachie et al., 2006). 
The biological effects of both cGMP pools are mediated by PKG activity (Francis, 2010). Other 
compartmentation of CNs also occurs in other organelles and the nucleus (Dodge-Kafka et al., 2006; 
Fischmeister et al., 2006). 
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Fischmeister and colleagues (2006) proposed that cAMP and cGMP compartmentalized signal 
generation is controlled by a relationship between distinct synthesis sites and restricted cytoplasmic 
diffusion. 
Intracellular CN levels are tightly regulated by their synthesis and degradation rate 
(Fischmeister et al., 2006). PDEs are the only enzymes that control CN levels by hydrolysis, and 
therefore PDEs largely control CN compartmentation (Miller & Yan, 2010), and can also serve as 
downstream effectors of cAMP and cGMP (Omori & Kotera, 2007). 
1.9 Role of PDEs in regulating CN levels 
PDE activity selectively catalyzes CN hydrolysis. PDEs directly target the 3’, 5’ cyclic phosphate bonds 
of cAMP and/or cGMP (Beavo, 1995; Bender & Beavo, 2006) to generate 5’ AMP and 5’ GMP 
(Francis et al., 2011). 
PDEs enclose a highly conserved catalytic site, with approximately 270 amino acids, but differ 
significantly in other protein regions, specifically within the C- and N-terminal regions 
(Knight & Yan, 2013). They are subdivided into 11 distinct families, based on: primary amino acid 
sequence, complete domain structure, and catalytic and regulatory sites (Knight & Yan, 2013; 
Maurice et al., 2003). The subdivided families are classified as cAMP-specific (PDE4, 7 and 8), 
cGMP-specific (PDE5, 6 and 9) and dual-specific (PDE1, 2, 3, 10 and 11) (Francis et al., 2011). 
The involvement of a specific PDE on cAMP and/or cGMP amplitude, duration, and location are 
regulated by numerous processes, including: phosphorylation, CN binding to the amino terminal 
allosteric regulatory site (GAF domains), expression level alterations, regulatory or anchoring protein 
interactions and reversible translocation between subcellular compartments (Francis et al., 2011). 
Worthy to note, is the statement made by Zaccolo (2006) “the compartmentalization of individual 
PDEs, rather than the total level of expression of the enzyme, appears to be of paramount importance 
in determining their effects on intracellular cAMP levels”. 
PDEs control cAMP and cGMP diffusion and can be targeted to specific subcellular compartments 
(Götz et al., 2014; Zaccolo et al., 2002). Specific PDE localization is thus important, for example PDE4 
is found to play a crucial role in regulating cAMP levels generated by β-AR agonist stimulation 
(Mongillo et al., 2004). In contrast, PDE3 regulates cAMP levels in a functionally distinct pool 
associated with sarcoplasmic Ca2+-ATPase (SERCA2), phospolamban, PKA inhibitory subunit 2, and 
protein phosphatase 2A (Knight & Yan, 2013). 
In the heart, the activity of specific localized PDEs control cAMP and cGMP levels and localization in a 
cross-talk fashion, for example cGMP levels regulate the activity of PDE2 to hydrolyse cAMP.  
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As a result, the intracellular cGMP level influences the intracellular cAMP level 
(Zaccolo & Movsesian, 2007). 
In the setting of acute myocardial ischemia the increase in cAMP can be detrimental. This damaging 
effect can be blunted, and protection stimulated, when cGMP levels increase (Yanaka et al., 2003). 
Remember that specific PDEs are responsible for cAMP and/or cGMP levels. Therefore it is 
necessary to identify the key PDEs that are damaging or protective during ischemia, and whether their 
inhibition or activation elicits cardioprotection. 
1.10 PDE5: cGMP specific enzymes 
PDE5 is the first cGMP-PDE discovered and remains the best characterized (Senzaki et al., 2001; 
Vandenwijngaert et al., 2013; Zhang et al., 2008). Three splice variants of PDE5 (A1 - A3) are 
identified in cardiomyocytes (Maurice et al., 2003). 
PDE5 is specific for cGMP hydrolysis and contains GAF (amino terminal allosteric regulatory site) 
domains, refer to Figure 1.4. PKA activates and phosphorylates PDE5 (Beavo, 1995). Alternatively 
and more frequently, PDE5 is phosphorylated by PKG (Rao & Xi, 2009). The binding of cGMP to GAF 
A activates PDE5 and mediates PKG phosphorylation (Das et al., 2005), which increases PDE5 
affinity for cGMP, and normalizes the levels of cGMP (Das et al., 2015). 
 
 
Figure 1.4 PDE5 domain organization. This figure is modified from (Francis et al., 2011). A conserved catalytic 
domain is located in the COOH-terminal portion. One GAF domain provides for allosteric cGMP binding and the 
other GAF domain regulates catalytic site functions. Phosphorylation site is indicated by the encircled P. 
1.10.1  The role and expression of PDE5 under normal physiological conditions 
Under normal physiological conditions PDE5 is predominately expressed in VSMC, platelets, brain, 
lung, kidney, skeletal muscle and at low levels in the cardiomyocyte (Rao & Xi, 2009). PDE5 is 
localized relative to the z-band sarcomere structure and the sarcoplasmic reticulum (Rao & Xi, 2009; 
Senzaki et al., 2001). 
NOS is suggested to be responsible for this localization. A study with endothelial NOS (eNOS) 
knockout mice and NOS inhibitor NG-nitro-L-arginine methylester (L-NAME) chronically treated 
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wild-type cardiomyocytes, showed diffused PDE5 distribution (Takimoto et al., 2005). A similar 
diffused PDE5 distribution is found in failing hearts, where the localization of PDE5 with the z-band is 
altered (Senzaki et al., 2001). 
PDE5 solely regulates NO-GC produced compartmentalized cGMP pools after β-AR stimulation 
(Götz et al., 2014; Senzaki et al., 2001). A cultured neonatal cardiomyocyte study by Isidori and 
colleagues (2015) examined the contribution of PDE5 to the isoproterenol stimulated contraction rate 
of all β-ARs. Their study showed that PDE5 inhibition increased cGMP levels and decreased the 
contraction rate from β-AR stimulation. Their study furthermore indicated that PDE5 inhibition 
counteracts β2-AR signaling via a localized cascade of cGMP and PDE2, where PDE2 hydrolyses a 
subtype-specific cAMP pool. This supports the knowledge of β-AR signaling compartmentalization. 
PDE5 activity influences cGMP physiological effects via PKG by maintaining vascular smooth muscle 
tone and directly affecting cardiomyocyte contractility (Maurice et al., 2003). 
1.10.2  The role and expression of PDE5 in acute myocardial ischemia 
PDE5 expression is found to increase in patients with ventricular hypertrophy and advanced left 
ventricle failure (Isidori et al., 2015; Johnson et al., 2012). Therefore, in the heart, PDE5 possibly 
exerts an adaptive role to an increase in stress (Vandenwijngaert et al., 2013). An increase in PDE5 
expression thus serves as a molecular hallmark in hypertrophic hearts (Zhang et al., 2008). 
Scientists developed the first selective PDE5 inhibitor (UK-92480) as part of a drug development 
program for antihypertension (Kumar et al., 2009). The drug was thought to augment intracellular 
cGMP levels to relax arteries and lower blood pressure, but the results were disappointing. 
As yet, three selective PDE5 inhibitors are used to treat erectile dysfunction: vardenafil (Levitra™), 
tadalafil (Cialis™), and sildenafil (Viagra™) (Das et al., 2015; Kukreja et al., 2004; 
Senzaki et al., 2001). PDE5 inhibitors are approved to treat pulmonary arterial hypertension 
(Choi et al., 2009; Kumar et al., 2009; Senzaki et al., 2001; Sesti et al., 2007), congestive heart failure 
(Kass, 2012; Weeks et al., 2005), diabetes and cancer (Das et al., 2015). 
Inhibition of PDE5 results in an elevated steady state of cGMP levels (Beavo, 1995; 
Cawley et al., 2007), which activates PKG. PKG opens the mitochondrial ATP-sensitive potassium 
(KATP) channels (Choi et al., 2009), stimulating protection in ischemic hearts by preventing ion gradient 
loss, allowing continued ATP production and Ca2+ transport out of the overloaded mitochondria 
(Rao & Xi, 2009; Takashi et al., 1999). Protection from I/R is also mediated by a PKG-dependent 
protein phosphorylation cascade, including ERK1/2 and glycogen synthase kinase-3 beta (GSK3β) 
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phosphorylation (Das et al., 2008), which decreases ICa2+ and results in vasodilation 
(Kukreja et al., 2004). 
There are significantly more studies based on PDE5 inhibition in I/R compared to PDE2 and PDE3. 
Most of these studies are described below and summarized in Table 1.1. 
Novel investigations of myocardial preconditioning (Ockaili et al., 2002; Salloum et al., 2003) with 
sildenafil in rabbits and mice isolated perfused hearts identified that PDE5 inhibition can reduce the 
infarct size and results in cardioprotection. The rabbits were treated in vivo with sildenafil either 
acutely, 30 min before, or chronically, 24 h before, 30-min ischemia and 3-h reperfusion 
(30-min I/3-h R) (Ockaili et al., 2002). Sildenafil also significantly reduced blood pressure. For the mice 
experiment, sildenafil was administered in vivo 24 h before 20-min I/30-min R (Salloum et al., 2003). 
The cardioprotection stimulated from preconditioning with sildenafil was dependant on the induction of 
NOS, where inducible NOS (iNOS) appeared to be the primary isoform that mediates protection. NOS 
induction lead to the opening of the mitochondrial KATP channel. 
The opening of the mitochondrial KATP channel was also identified as the possible end-effector of 
preconditioning with sildenafil in isolated rat hearts, where sildenafil was given 10 min before either 
20-min global I/5-min R or 35-min regional I/30-min R (du Toit et al., 2005). This group, using 
radio-immunoassay kits, showed that sildenafil elevates myocardial cGMP levels and directly 
suppresses cAMP levels. 
Salloum and colleagues (2006) confirmed that the opening of the mitochondrial KATP channel is crucial 
in perfused rabbit hearts. They found that preconditoning with vardenafil 30 min before 30-min I/3-h R 
induced protection from I/R injury. Even in infant rabbits (Bremer et al., 2005), in vivo treatment with 
sildenafil 30 min before 30-min I/3-h R also reduced the infarct size and preserved left ventricular 
cardiac output. 
The same preconditioning effect was found by Das and colleagues (2002) in isolated perfused rat 
hearts, where in vivo administration of sildenafil 60 min before 30-min I/2-h R improved ventricular 
recovery, decreased infarct, and reduced the incidence of ventricular fibrillation. 
The hypothesis behind these studies is that the vasodilatory effect of sildenafil, administered acutely 
or delayed, could possibly release endogenous preconditioning mediators, such as adenosine or 
bradykinin, from endothelial cells. These mediators potentially trigger a signaling cascade via kinase 
activity and results in NOS phosphorylation and NO release. NO can activate GC, which enhances 
cGMP levels and leads to kinase activation, such as PKG and PKC. Subsequently, PKG and PKC 
leads to the opening of the mitochondrial KATP channel and stimulates cardioprotection 
(Kukreja et al., 2004). Das and colleagues elaborated their results in 2009 and found that 
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preconditioning with sildenafil increases PKG-dependant ERK1/2 and GSK3β phosphorylation 
significantly, where ERK phosphorylaton is crucial for the induction of eNOS, iNOS, increasing B-cell 
lymphoma-2 (Bcl-2) and the resulting cardioprotective effect. 
With regards to isolated cardiomyocytes, an in vitro study (Das et al., 2005) found that sildenafil 
(1 μM or 10 μM) given 1 h before 40-min simulated I/18-h R significantly reduced apoptosis and 
necrosis by enhancing the induction of iNOS and eNOS (too a smaller extent), increasing NO, which 
up-regulates Bcl-2. In 2006 the research group (Das et al., 2006) confirmed that the rise in PKG 
activity from sildenafil treatment plays a crucial role in protecting cardiomyocytes from necrosis and 
apoptosis by increasing PKB/Akt, ERK1/2, and c-Jun N-terminal kinase (JNK) phosphorylation, Bcl-2, 
iNOS, eNOS and decreasing the expression of the pro-apoptotic protein, Bax. 
It seems that research based on per- and post- I/R inhibition of PDE5 is limited, in fact, I could find 
only one article. The first research group that tested the inhibition of PDE5 at reperfusion was Salloum 
and colleagues (2007). 
In rabbit hearts they found that the administration of sildenafil or vadenafil 5 min before reperfusion for 
65 min with the protocol of 30-min I/3-h R decreased the infarct size in a similar mechanism as 
preconditioning, by opening the mitochondrial KATP channel. 
Table 1.1 PDE5 inhibitors administrated at different time points during ischemia-reperfusion (I/R) to induce 
cardioprotection. 
Drug Animal model Time point Drug effect Authors 
Sildenafil 
Perfused adult rabbit heart 
Before I/R 
Reduced infarct size (Ockaili et al., 2002) 
Isolate rat heart 
Improved ventricular 
recovery, decreased 
myocardial infarction and 
reduced incidence of 
ventricular fibrillation 
(Das et al., 2002) 
Perfused mice hearts Reduced infarct size (Salloum et al., 2003) 
Perfused infant rabbit 
heart 
Reduced infarct size and 
preserved left ventricular 
cardiac output 
(Bremer et al., 2005) 
Isolated ventricular 
cardiomyocytes 
Reduced apoptosis and 
necrosis 
(Das et al., 2005) 
Isolated rat heart Reduced infarct size (du Toit et al., 2005) 
Vardenafil Perfused rabbit hearts Stimulated I/R protection  (Salloum et al., 2006) 
Tadalafil Isolated rat hearts 
Reduced mean arterial 
pressure and infarct size 
(Sesti et al., 2007) 
Tadalafil Isolated mouse hearts Reduced apoptosis (Ahmad et al., 2009)  
Sildenafil Isolated mouse hearts Reduced infarct size (Das et al., 2009) 
Sildenafil/ 
vardenafil 
Perfused adult rabbit heart Onset R Reduced infarct size (Salloum et al., 2007) 
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PDE5 inhibition before I/R has frequently been proven to be protective (Ahmad et al., 2009; 
Bremer et al., 2005; Das et al., 2009; Das et al., 2002; du Toit et al., 2005; Kukreja et al., 2005; 
Ockaili et al., 2002; Salloum et al., 2006; Salloum et al., 2003; Sesti et al., 2007) and PDE5 inhibition 
at reperfusion (Salloum et al., 2007), by a similar mechanism as preconditioning, can stimulate 
cardioprotection. There is a major lack in research on the role of PDE5 in cultured isolated 
cardiomyocytes, and when PDE5 is inhibited at the onset of ischemia, at reperfusion or after I/R. This 
study aims to address this shortcoming. 
However, PDEs do not function in isolation, and the activity or the inhibition of various PDEs might 
play an important role in mediating the cardioprotection stimulated by PDE5 inhibition. In the next 
section the PDEs that could be involved are identified and their specific role and expression under 
normal physiological conditions and in acute myocardial ischemia are explored.  
1.11 Cardiomyocyte cAMP and cGMP cross-talk with PDE5 
Isidori and colleagues (2015) found that PDE5 inhibition (with sildenafil) modulates the response of β-
AR stimulation (isoproterenol) by influencing PDE2 activity, refer to Figure 1.6. After β-AR stimulation, 
PDE2 inhibition (with erythro-9-(2-hydroxyl-3-nonyl)adenine: EHNA) reversed the negative 
chronotropic effects of PDE5 inhibition. They proposed the following: the inhibition of PDE5 leads to 
an increase in cGMP levels. The high levels of cGMP activate PDE2 to hydrolyse cAMP, which were 
increased by β-AR stimulation. 
A cross-talk between PDE5 and PDE3 contributes to the regulation of cGMP (Rao & Xi, 2009). In 
cardiomyocytes, cGMP influences Ca2+ levels via cAMP in a manner that is concentration dependent. 
Low cGMP concentrations inhibit PDE3 and increases Ca2+ levels (Figure 1.5A), while high cGMP 
concentrations activate PDE2 and decreases Ca2+ levels (Figure 1.5B) (Rao & Xi, 2009). 
 
Figure 1.5 A) Low cGMP concentrations inhibit PDE3. PDE3 cannot hydrolyse cAMP and Ca
2+
 levels increase. 
PDE5 regulates cGMP levels B) High cGMP concentrations activate PDE2. PDE2 hydrolyses cAMP and Ca
2+
 
levels decrease. 
↓ cGMP 
PDE3 
↑ cAMP → ↑Ca2+ 
↑ cGMP 
PDE2 
↓cAMP → ↓Ca2+ 
PDE5 
A) 
B) 
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Taken together, refer to Figure 1.6, PDE2 and PDE3 mediate contrasting regulation 
(Bender & Beavo, 2006; Maurice et al., 2003). The cGMP-stimulated PDE2 and cGMP-inhibited PDE3 
regulate cAMP signaling in the cardiomyocytes. cGMP-mediated PDE2 activation acts to limit the 
cAMP levels and Ca2+ current, stimulated by the cGMP-mediated effect on PDE3 
(Maurice et al., 2003). Under conditions where cGMP levels are low and PDE2 and PDE3 are 
inhibited, it seems that PDE3 plays a more prominent role in regulating cAMP 
(Bender & Beavo, 2006). Compared to the effect of PDE2 inhibition, PDE3 inhibitors (for example 
milrinone) alone have a greater effect on platelet aggregation. 
Wen and colleagues (2004) proposed that soluble GC (sGC) and particulate GC (pGC) both regulate 
cGMP/PDE/cAMP signaling (refer to Figure 1.6). sGC and pGC are possibly related to functional 
cGMP compartments attributable to localized accumulation in cGMP (Wen et al., 2004). Therefore, the 
roles of PDE2 and PDE3 are related to the two phase effect of cGMP on cardiac Ca2+ current. 
 
Figure 1.6 Schematic summary of PDE5 cross-talk with PDE2 and PDE3 in cardiomyocytes, adapted from 
(Rao & Xi, 2009). β-AR stimulation increases cAMP via AC, activating PKA, which leads to cardio damage. ANP 
stimulation increases cGMP via pGC. cGMP is also increased by NO via sGC. cGMP activates PKG, which 
leads to cardioprotection. PKA activates and phosphorylates both PDE3 and 5. PDE5 can also be activated and 
phosphorylated by PKG. An increase in cGMP activates PDE2 (inhibitor: EHNA) to hydrolyse cAMP. Low levels 
of cGMP furthermore inhibits PDE3 (inhibitor: milrinone) leading to an increase in cAMP. Active PDE5 
(inhibitor: sildenafil) hydrolyses cGMP. PDEs, and their inhibition, tightly regulate cAMP and/or cAMP levels. 
cGMP 
PKG 
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1.12 PDE2: cGMP stimulated to hydrolyse cAMP and cGMP 
PDE2 (splice variants: A1, A2 and A3) is a dual-specific PDE and hydrolyses both cAMP (Km = 30 μM) 
and cGMP (Km = 10 μM) (Fischmeister et al., 1995; Zaccolo et al., 2006). However, only cGMP 
binding to any one of the two GAF domains (refer to Figure 1.7), via allosteric modification, can 
activate PDE2 (Bender & Beavo, 2006; Maurice et al., 2003). 
 
 
Figure 1.7 PDE2 domain organization. This figure is modified from (Francis et al., 2011). A conserved catalytic 
domain is located in the COOH-terminal portion. One GAF domain provides for allosteric cGMP binding and the 
other GAF domain regulates catalytic site functions. 
 
The binding of cGMP lowers the affinity of PDE2 for cAMP by 30-fold (Knight & Yan, 2013), activates 
PDE2 activity to hydrolyse cAMP (Zaccolo & Movsesian, 2007), which is quantitatively more important 
than the competitive inhibition of cAMP hydrolysis. cAMP hydrolysis can be inhibited when cGMP 
concentrations are high (> 50 μM) (Zaccolo & Movsesian, 2007) and results in PDE2 hydrolyzing 
cGMP (Mokni et al., 2010; Vandecasteele et al., 2001), where PDE2 is mainly associate with pGC 
produced cGMP pools (Knight & Yan, 2013). 
Interestingly, in adult cardiomyocytes, only β3-AR coupled NOS-NO derived cGMP can bind to the 
GAF domains. cGMP derived from ANP receptor without concomitant β-AR stimulation cannot bind 
the GAF domains. This is contradictory to what is found in neonatal cardiomyocytes, where cGMP 
from both pathways can activate PDE2 (Lee & Kass, 2012). This indicates the development of 
complex compartmentalized signaling in adult cardiomyocytes. 
1.12.1  The role and expression of PDE2 under normal physiological conditions 
Under basal conditions PDE2 expression, refer to Figure 1.8, is found in the isolated cardiomyocyte 
(Francis et al., 2011). PDE2 is encoded by a single gene that is alternatively spliced to produce three 
isoforms: A1 – A3. PDE2A2 and PDE2A3 show clear distinct membrane localization, indicating 
anchoring to compartments. Distribution is found to be at the sarcolemma, sarcoplasmic reticulum 
membrane (Zaccolo et al., 2006), and the z-line (Takimoto, 2012). Both isomers are functionally 
coupled to a pool of AC activated by β-AR stimulation where they primarily regulate cAMP originating 
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from this compartment. PDE2A1, attributable to the absence of a unique N-terminal amino acid 
sequence, is soluble and found in the cytoplasm (Bender & Beavo, 2006). Once activated, PDE2 
reduces L-type Ca2+ currents and blunts contraction (Knight & Yan, 2013; Maurice et al., 2003). 
PDE2 represents only 1 % of total PDE activity for cAMP at basal (Mongillo et al., 2006). Despite the 
marginal PDE2 activity, (Zaccolo et al., 2006) showed that PDE2 inhibition, in combination with 
β-AR-agonists, greatly elevates cAMP levels. This proves the important role of PDE2 in controlling the 
cAMP response to catecholamines. 
 
 
Figure 1.8 Schematic representation of PDE2 localization and cAMP compartmentalization in cardiomyocytes. 
PDE2A2 and PDE2A3 are functionally coupled to AC pools activated by specific GPCR β-AR stimulation. cGMP 
activates PDE2 activity to hydrolyse cAMP, and at high concentrations cGMP, localized in specific 
compartments. 
 
Normoxic cardiomyocyte studies show that cGMP, through activating PDE2, opposes cAMP by 
reducing cAMP levels and directly affects cardiac function (Fischmeister et al., 1995; 
Vandecasteele et al., 2001). 
1.12.2  The role and expression of PDE2 in acute myocardial ischemia 
Nothing is known about the role of PDE2 in the setting of I/R. Studies with Angiotensin-II-induced 
hypertrophy in rat whole hearts (Mokni et al., 2010) and ventricles subjected to pressure overload 
(Yanaka et al., 2003) provide evidence that PDE2’s activity to hydrolyse cAMP increases in heart 
diseases. The potent PDE2 inhibitor, EHNA (Abi-Gerges et al., 2000; Maurice et al., 2003; Mokni et 
al., 2010; Vandecasteele et al., 2001) is however frequently used in studies to block cAMP hydrolysis. 
As explained in section 1.2, detrimental levels of cAMP cause damage during ischemia. The prediction 
can be made that, if the activity of PDE2 is increased during acute myocardial ischemia, by inhibiting 
β-AR 
PDE2 
cAMP 
 cGMP 
↑ [cGMP] 
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cGMP-specific PDEs to increase cGMP levels, the levels of cAMP will decrease and cardioprotection 
can be stimulated. 
1.13 PDE3: cGMP-inhibited cAMP-hydrolysing enzymes 
PDE3 (subfamilies: A and B) regulates both cAMP- and cGMP-mediated intracellular signaling 
(Isidori et al., 2015; Wechsler et al., 2002). The binding affinity for cAMP (Km < 0.4 μM) and cGMP 
(Km < 0.3 μM) is equally high (Bender & Beavo, 2006), and hydrolysis of both is done in a mutually 
competitive fashion (Wechsler et al., 2002). 
The C-terminal catalytic domain of PDE3, refer to Figure 1.9, contributes to catalytic activity and 
inhibitor selectivity by expressing a unique 44 amino acid sequence (Maurice et al., 2003). The 
catalytic rate for cAMP is 10-fold higher compared to cGMP. The slower hydrolysis of cGMP allows 
cAMP to be spared which is how cGMP inhibits PDE3 hydrolysis of cAMP (Zaccolo & Movsesian, 
2007). 
PDE3 also contains N-terminal hydrophobic membrane association regions, named NHR1 and NHR2, 
refer to Figure 1.9. These regions control PDE3 localization and thereby influence PDE3 activity 
(Zaccolo & Movsesian, 2007). PKA or PKB/Akt phosphorylation activates PDE3 at consensus sites of 
phosphorylation for each kinase located between NHR2 and the catalytic domain 
(Maurice et al., 2003). 
 
 
Figure 1.9 PDE3 domain organization. This figure is modified from (Francis et al., 2011). A conserved catalytic 
domain is located in the COOH-terminal portion. Phosphorylation sites are indicated by the encircled P. A unique 
complement of NHR1 and NHR2 contribute to activity regulation. 
 
1.13.1  The role and expression of PDE3 under normal physiological conditions 
The PDE3 isoforms, A and B, are structurally similar, but differences can be found in the catalytic 
domain, where they have different 44-amino acid sequences, and in the N-terminal, where they have 
different regions (Wechsler et al., 2002). Although the isoforms have similar pharmacological and 
kinetic properties there is a distinction in the expression profiles. PDE3A expression is more abundant 
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than PDE3B, and primarily found in cardio and vascular myocytes (Maurice et al., 2003). PDE3A is 
localized in cytosolic and microsomal compartments, in close proximity to selective cAMP pools, 
associated with SERCA2, phospolamban, PKA inhibitory subunit 2, and protein phosphatase 2A 
(Knight & Yan, 2013). These pools can be regulated by direct PDE3 regulation (Wechsler et al., 2002). 
PDE3B expression is found in pancreatic cells, hepatocytes, and adipocytes (Rao & Xi, 2009; 
Wechsler et al., 2002). 
In cardiomyocytes, at basal level, the cAMP-hydrolysing activity of PDE3 is abundant 
(Francis et al., 2011; Johnson et al., 2012; Maurice et al., 2003). Together, PDE3 and PDE4 are 
mainly responsible to control ICa2+ for contraction and relaxation (Johnson et al., 2012). 
PDE3 activity controls ICa2+ levels in a PKA-dependent manner (Kirstein et al., 1995) through L-type 
Ca2+ channels and SERCA2 (Wechsler et al., 2002). ICa2+ release is induced via a NO-cGMP pathway 
in the following manner. Low levels of NO stimulates sGC to produce cGMP, which inhibits PDE3, 
increasing the cAMP levels and thereby stimulates an increase in ICa2+ (Vandecasteele et al., 2001). 
cGMP produced by pGC when stimulated by natriuretic peptides also inhibits PDE3 
(Götz et al., 2014). Interestingly, a perfused beating rabbit atrial study (Wen et al., 2004) indicated that 
cGMP production from sGC or pGC has different effects on cAMP levels, suggesting 
compartmentalization of cGMP/PDE3/cAMP signaling. The different effects have not yet been 
clarified. Nonetheless, these cGMP pools are responsible for the “cross-talk” between cAMP and 
cGMP (Götz et al., 2014). 
β1- and β2-AR cAMP-mediated signaling is regulated by PDE3 (Fischmeister et al., 2006). Yet it is 
suggested that PDE3 is mainly associated with β2-ARs. PDE3 blunts the response of β2-AR, 
activated by catecholamine release, to increase cAMP levels (Christ et al., 2009). Nikoleav and 
colleagues (2006) proposed that cAMP stimulated by β1-AR generates a cAMP gradient, which 
propagates throughout the cell, whereas β2-AR cAMP signaling remains locally restricted in 
compartments. 
1.13.2  The role and expression of PDE3 in acute myocardial ischemia 
The chronic inhibition of PDE3 in heart failure is vastly studied, but limited publications have focused 
on the role PDE3 inhibition exerts during acute myocardial ischemia. Nevertheless, what is known of 
cardioprotection exerted by PDE3 inhibitors is described below. 
In cardiomyocytes the inhibition of PDE3 elevates cAMP levels and the L-type Ca2+ currents 
(Wechsler et al., 2002), resulting in positive inotropic (contraction) and vasodilatory (relaxation) effects 
(Miller & Yan, 2010; Rao & Xi, 2009). Milrinone, a selective inhibitor of PDE3, is commonly used to 
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treat congestive heart failure due to the positive inotropic effects (Francis et al., 2011; 
Miller & Yan, 2010; Zaccolo & Movsesian, 2007). It is a major concern that mortality is found to 
increase with chronic milrinone treatment, mainly attributable to arrhythmias and sudden death 
(Miller & Yan, 2010). 
Chronic PDE3 inhibition promotes apoptosis (Zaccolo et al., 2005) potentially via increased localized 
cAMP that sustains the induction of inducible cAMP early repressor (ICER) transcription 
(Tomita et al., 2003). ICER mediates apoptosis partially through the cAMP response element binding 
protein (CREB)-mediated transcription inhibition and Bcl-2 downregulation (Ding et al., 2005; Shin et 
al., 2014; Tomita et al., 2003). In contrast, PDE3 overexpression prevents cardiomyocyte death (Shin 
et al., 2014). 
Some studies regarding the role of PDE3 inhibition (with milrinone or amrinone) on ischemic and 
hypoxic hearts will now be described and are summarized in Table 1.2. 
In 1992, Löwe and Jacobsohn found that in a perfused rabbit heart, where milrinone was continuously 
administered in a perfusion medium during 5 min hypoxia and 15 min reperfusion (5-min H/15-min R), 
improved contractile recovery, but the mechanism involved was not described. 
Experiments that followed by other researchers (Sanada et al., 2001; Shibata et al., 2013) identified 
the role of PDE3 in the cAMP/PKA/p38 MEK-dependent pathway that stimulates cardio damage. 
PDE3 inhibition with milrinone, 30 min before 90 min I/6 h R, increases cAMP, which activates PKA to 
elicit protection (Sanada et al., 2001). The same result was found when PDE3 was inhibited 20 min 
directly after 12-min I/90-min R or 20-min after I/R for 70 min (Shibata et al., 2013). Sanada and 
colleagues (2001) also found that PDE3 plays a role in the PKC-independent pathway, however the 
precise mechanism involved is still elusive. 
PDE3 inhibition after acute ischemia has an inotropic effect (Zucchi et al., 1990) also when amrinone 
was given 20 min before 30-min I/30-min R (Rechtman et al., 2000). The inotropic effect identifies the 
role PDE3 inhibition exerts to increase Ca2+ levels, which correlates with the cAMP/PKA/p38 
MEK-dependent pathway. 
In a rat heart model, Huang and colleagues (2011) found that Milrinone, in combination with a β1-AR 
blocker, administered for 10 min from the last 5 min of ischemia until the initial 5 min of reperfusion, 
robustly reduced left ventricular myocardial infarct size via PKA and subsequent PKB/Akt activation. 
This indicates that active PDE3 plays a role in activating apoptosis, which they confirmed in rat 
isolated cardiomyocyte cultures that underwent 2-h H/1-h R. 
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Table 1.2 PDE3 inhibitors administrated at different time points during ischemia-reperfusion (I/R) or hypoxia-
reperfusion (H/R) to induce cardioprotection. 
 
Studies to determine the role of acute PDE3 inhibition in the setting of acute myocardial ischemia is 
still lacking, in isolated cardiomyocytes even more so than in heart model experiments. As acute 
PDE3 inhibition does not activate apoptosis, and the experiments described above prove PDE3 
inhibition initiates cardioprotection, the prediction can be made that PDE3 inhibition during acute 
myocardial ischemia in isolated cardiomyocytes will stimulate protection. Possibly, this protection is 
induced by the activation of the cAMP/PKA/p38 MEK-dependent pathway to increase ICa2+. 
It is, however, very interesting that the increase in cAMP from PDE3 inhibition leads to protection, as 
increased cAMP levels are usually associated with contraction and damage (section 1.2). 
 
 
Drug Animal model I/R or H/R 
Drug 
administration 
Drug effect Authors 
Milrinone 
Perfused rabbit 
heart 
H/R During H/R 
Improved contractile 
recovery 
(Löwe & 
Jacobsohn, 1992) 
Canine heart I/R Before I/R Reduced infarct size 
(Sanada et al., 
2001) 
Swine heart I/R 
Onset of R or 20 
min after R 
Onset of R: Attenuated 
myocardial stunning 
(Shibata et al., 
2013) 
Amrinone 
Isolated rat 
heart 
I/R After I/R 
Improved contractile 
recovery 
(Zucchi et al., 
1990) 
Perfused rabbit 
heart 
I/R Before I/R 
Reduced infarct size 
and reduced incidences 
of ventricullar fibrillation 
(Saltman et al., 
2000) 
Isolated rat 
heart 
I/R Before I//R Reduced I/R injury 
(Rechtman et al., 
2000) 
Milrinone 
+ Esmolol 
(β1 
blocker) 
Isolated rat 
heart 
I/R Late I/ early R 
Reduced left ventricular 
myocardial infarct size (Huang et al., 
2011) Cultured 
cardiomyocytes 
H/R During H 
Reduced myocyte 
death rates 
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  CHAPTER 2
Hypothesis, Aims, Objectives and Value of Research 
In summary, acute myocardial I/R induces injury in cardiomyocytes that can be blunted, and protection 
can be stimulated, with the application of different treatments. The increase in cAMP during ischemia 
can be detrimental, whereas an increase in cGMP stimulates cardioprotection. PDEs control these 
cAMP/cGMP levels (Fischmeister et al., 2006). 
The inhibition of PDE5 is cardioprotective (Ockaili et al., 2002; Das et al., 2015) and leads to an 
increase in cGMP, which can possibly suppress the damaging effect of the increase in cAMP from β-
AR activation. We therefore speculate that the compartmentalization of cAMP/cGMP plays a critical 
role in governing protection versus damage signaling during I/R. 
CBD has already been shown to protect the isolated whole heart (Durst et al., 2007; Feng et al., 2015; 
Walsh et al., 2010) and might therefore also protect isolated heart cells. CBD possibly protect heart 
cells against I/R injury by activating CB receptors that couple to Gi and thereby increase cGMP 
(Carney et al., 2009). This CBD-mediated protection might be controlled by specific PDEs, possibly 
PDE5. 
2.1 Hypothesis 
We hypothesize that acute myocardial I/R injury can be blunted, and protection stimulated with the 
PDE5 inhibitor, and that CBD-mediated protection is dependent on the inhibition of PDE5. 
2.2 Aims 
The main aim of this study was to determine the role of PDE5 in regulating cardioprotection versus 
damage. 
The second aim was to determine if CBD protects cardiomyocytes against I/R injury and whether the 
protection is dependent on the inhibition of PDE5. 
2.3 Objectives 
1. To evaluate whether CBD at 0.001 μM, 1 μM, or 100 μM can protect adult rat cardiomyocytes from 
I/R damage, specifically contracture/hypercontracture and apoptosis.  
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2. a) To determine if the inhibition of PDE5 during ischemia protect cardiomyocytes against I/R 
damage. 
b) To determine if the inhibition of PDE5 during ischemia protect cardiomyocytes against 
enhanced I/R damage, driven by general β-ARs stimulation with isoproterenol, or β1-AR 
stimulation with dobutamine. 
c) To determine if, when β2-AR stimulation with formoterol protects cardiomyocytes against I/R 
damage, PDE5 inhibition further enhance protection. 
3. To evaluate if protection elicited by CBD depends on PDE5 inhibition. 
4. To investigate whether greater protection can be elicited by CBD in combination with the PDE5 
inhibitor. 
The objectives for Part 1 of this study could not be met and new objectives in Part 2 of this study 
focused on evaluating where the problem was. 
2.4 Value research contributes to society 
Heart attacks are the cause of too many deaths globally. The treatments currently available are found 
to be mostly protective when given as preconditioning, which is clinically not relevant, as normally a 
heart attack cannot be predicted. There is a need to identify novel treatments that can intervene during 
ischemia or during reperfusion. This project will contribute by identifying alternative treatments that 
stimulate protection, evaluating CBD with and without the PDE5 inhibitor. CBD is non-psychoactive, 
does not exert any harmful effects, and can easily be extracted from the plant Cannabis sativa. 
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  CHAPTER 3
Materials and Methods 
3.1 Animals 
Adult male Wistar rats (260 - 290 g) were bred and housed in an internationally accredited AAALAC 
(association for assessment and accreditation of laboratory animal care) from the Faculty of Medicine 
and Health Sciences, Stellenbosch University. The animals had free access to standard lab food and 
water, and were maintained on a 12 h day/night cycle. 
3.2 Ethical approval 
Ethical approval was granted for the project by the Animal Ethics committee of the University of 
Stellenbosch (Faculty of Health Sciences) with project number SU–ACUM13-00018. The project 
conformed to the conditions stated in the “Revised South African National Standard for the care and 
use of Animals for Scientific purposes” (South African Bureau of Standards, SANS 10386, 2008). 
3.3 Reagents 
All reagents were obtained from Sigma-Aldrich, unless specified as other. Where necessary, the 
chemicals were stored at -4 ˚C and -20 ˚C. 
3.4 Coating culture surface with Laminin-Entactin adhesive 
96-well clear bottom tissue culture plates were used for all experiments. Laminin-Entactin 
(L/E, obtained from Lilly) was diluted to 100 μg/ml in PBS (6 mM KCl, 1 mM Na2HPO4, 0.2 mM, 
NaH2PO4.H20, 1.4 mM MgSO4.7H20, 128 mM NaCl, 1.2 mM Ca
2+, and 10 mM Hepes). 5 μl L/E was 
pipetted in the centre of each well and incubated overnight at 5 % CO₂ and 37 ˚С. The next day the 
L/E was removed, the wells washed (x 2) with 100 μl PBS and air dried in the laminar flow cabinet. 
3.5 Isolation of adult rat ventricular cardiomyocytes  
The Langendorff perfusion system was assembled in a laminar flow cabinet and thoroughly rinsed with 
sterile ethanol and left to dry. The ventricular cardiomyocytes were isolated using a modified 
Stellenbosch University  https://scholar.sun.ac.za
30 
 
enzymatic technique (Fischer et al., 1991). All isolation buffers were continuously gassed with 5 % 
CO2 and 95 % O2 and contained 1 % penicillin/streptomycin (BD Biosciences). 
In brief each rat was anesthetized with 60 mg sodium pentobarbital (Bayer), the heart removed and 
retrograde perfused (37 °C) with buffer A (Ca2+ free PBS with 11 mM D-glucose, 2 mM pyruvate and, 
3 mIU/ml insulin (Humulin R by Lilly)) for 5 min. Enzymatic digestion was commenced by perfusion 
with buffer B (buffer A containing 0.5 % fatty acid free bovine serum albumin (BSA, obtained from 
Roche), 18 mM 2,3-butanedione monoxim (BDM), 1.8 mg/ml collagenase II (240 U/mg Worthington), 
and 0.2 mg/ml protease type IV (≥ 3.5 U/mg). Ca2+ was increased with 0.1 mM increments at 10 and 
20 min thereafter. The digested ventricular tissue was cut off, placed in a petri dish and gently shook 
in buffer D (5 ml buffer B and 10 ml buffer C) with tweezers to facilitate cell dissociation. The cells 
were filtered through a 200 μm mesh and pelleted by 1 min centrifugation at 60 g. The cell pellet was 
re-suspended in buffer C (buffer A containing 0.5 % BSA, 0.5 % BSA fatty acid free, and 9 mM BDM) 
and the Ca2+ sequentially increased to 0.6, 0.9, and finally 1.2 mM. 
150 μl cell suspension was removed and cells counted under the light microscope to determine 
percentage cell viability. The cells were diluted in a modified M199 culture buffer (40 % M199 
supplemented with 10 mM HEPES, 5 mM creatine, 5 mM carnitine, 5 mM taurine mixed with 60 % 
buffer C containing 1.2 mM Ca2+ but not BDM) with 10 μM blebbistatin. The cells were counted under 
the light microscope using a hemocytometer. For normoxic conditions a final concentration of 2500 
cells/100 μl/well was used, while 5000 cells/100 μl/well were used for ischemic experiments. Under 
ischemic conditions more cells wash off of the plate compared to the normoxic conditions, and to 
compensate for the loss of cells more cells are plated for ischemia experiments. The isolated 
cardiomyocytes were then seeded in the 96-well clear bottom L/E coated plates and cultured overnight 
in the incubator at 5 % CO2 and 37 °C. 
3.6 I/R and JC-1 staining 
Cardiomyocytes were washed (x 3) for 30 min with modified M199 culture buffer (without blebbistatin), 
followed by simulated ischemia. 2-deoxy-D-3[H]glucose (2DG), which inhibits glycolysis, and sodium 
dithionite (SDT), an oxygen scavenger that generates superoxide radicals, were the chemical drugs 
used to simulate ischemia. Simulated ischemia was induced for 20 min by ischemic wash (40 % M199 
with 1 % penicillin/streptomycin, and 60 % PBS containing 1.2 mM Ca2+ (without HEPES), pH = 6.4) 
with 3 mM 2DG and 10 mM SDT (Figure 3.1). Ischemia was followed by 60 min reperfusion with 
modified M199 culture buffer (without blebbistatin), which included 15 min incubation with 15 μM JC-1 
stain, two washes and 30 min stain development, before images were captured (Figure 3.1). 
Normoxic cells received the same number of buffer changes as I/R, followed by JC-1 staining. JC-1 
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(5,5’,6,6’-tetrachloro-1,1’,3,3’-tetraethylbenzimidazole-carbocyanide iodine) stains the cytosol green, 
while only viable mitochondria with an active membrane potential difference will stain red. Therefore, a 
fluorescence ratio of red over green (R/G) indicates mitochondrial function, and thus cellular viability. 
Each experimental condition was repeated on cardiomyocytes harvested from 4 – 8 different rats, to 
yield n = 4 – 8. For each treatment group per heart there was at least 3 images, repeats, with 40 – 50 
cardiomyocytes per image. 
 
 
 
Figure 3.1 Protocol for 20 min simulated ischemia (3 mM 2DG and 10 mM SDT) followed by 60 min reperfusion, 
which included 15 min JC-1 stain. 
3.7 Drug concentrations 
 Non-selective β-ARs: 100 nM isoproterenol 
 β1-AR: 10 μM dobutamine 
 β2-AR: 10 μM formoterol (donated by Dr R. Salie (Tocris)) 
 CBD: 0.001 μM, 1 μM, and 100 μM 
 PDE5 inhibitor: 10 μM Sildenafil 
A. Per-treatment 
B. Continuously during ischemia  
     and reperfusion 
Ischemic wash with 
3 mM 2DG + 10 mM SDT 
Modified M199 culture buffer 
  
  80   50   35   20 -30 
Ischemia Reperfusion JC-1 
  0 
 Stain development 
Microscope 
Data 
Overnight 
culture 
 Stabilization  
A. Per-treatment drugs: 
 Non-selective β-ARs 
 β1-AR agonist 
 β2-AR agonist 
 CBD 
 PDE5 inhibitor 
Drugs administered 
B. Continuously during ischemia        
and reperfusion: 
 CBD 
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3.8 Data collection and analysis 
The Nikon fluorescence microscope was used to capture images following JC-1 staining. A dual band 
excitation filter was used, which allowed red and green fluorescence emission detection. The 
NIS-element Basic Research imaging software (Nikon) was used to capture images at a 100 x 
magnification. 
ImageJ (Schneider et al., 2012) freeware was used for image analysis to determine cell viability and 
R/G fluorescence. The “freehand tool” was selected and used to manually draw the shape outlines of 
the cells, the fluorescence ratio of the cell measured. Viability according to morphology was done by 
visually counting the total number of rod shaped viable cells, versus round shaped non-viable cells. 
The entire cell population within an image was analysed, excluding cells that overlapped and were 
partly outside the image. 
3.9 Statistics 
Data are presented as mean ± SEM. GraphPad Prism® 6 was used for graph plotting and analysis 
done with one-way analysis of variance (ANOVA) multiple comparison and Bonferonni post hoc test. 
p ≤ 0.05 was considered to be statistically significant. 
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  CHAPTER 4
Results 
The results of this study were obtained by evaluating the following endpoints: 
1. Cell viability according to morphology 
2. R/G fluorescence intensity of JC-1 to measure mitochondrial function. 
Both parameters can be used to determine the degree of damage or survival of cardiomyocytes 
(Geisbuhler et al., 2002; Stapleton & Allshire, 1998). The average cell viability is commonly measured 
according to morphology. An increase in the amount of rod shaped cells would indicate protection, 
and can be presented as the percentage viable cells in the total population. The R/G fluorescence 
ratio was determined and given as percentage of untreated normoxic cardiomyocytes. A high 
percentage would mean that red fluorescence intensity was high and green fluorescence intensity was 
low, indicating a viable population where mitochondrial function is high. A low percentage, where 
green fluorescence intensity was high and red fluorescence intensity was low, would indicate a 
population that consists mainly of cardiomyocytes with low mitochondrial function, and can be 
considered non-viable or destined for apoptosis. 
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4.1 The effect that different CBD concentrations exert during normoxia, ischemia 
and I/R on isolated ventricular cardiomyocytes survival 
Objective 1: 
To evaluate whether CBD at 0.001 μM, 1 μM, or 100 μM can protect adult rat cardiomyocytes from 
I/R damage, specifically contracture/hypercontracture and apoptosis. 
CBD concentrations, 0.001 μM, 1 μM, or 100 μM, were administered during normoxia to determine 
cytotoxicity. Representative fluorescence images for cell viability and R/G fluorescence can be seen in 
Figure 4.1, where normoxia without CBD (A) is given, and then normoxia with 0.001 μM (B), 1 μM (C) 
and 100 μM (D) CBD. 
Ischemia was induced for 20 min and reperfusion for 60 min, and is represented by (E). It was then 
determined if CBD could protect the isolated cardiomyocytes against I/R injury. The CBD 
concentrations were administered either during ischemia only, as can be seen in Figure 4.1 for 
0.001 μM (F), 1 μM (G), or 100 μM (H) CBD, or throughout ischemia and reperfusion, as can be seen 
for 0.001 μM (I), 1 μM (J), or 100 μM (K) CBD. Four hearts (n = 4), with two repeats per heart for each 
treatment group were analysed, except for I/R without CBD, which had 4 repeats per heart. The 
isolations yielded an average cell viability of 84 %. 
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Figure 4.1 Representative fluorescence images of isolated ventricular cardiomyocytes treated with different 
CBD concentrations during normoxia, ischemia and I/R. Normoxic control without CBD treatment is represented 
by (A). CBD was then administered during normoxia, 0.001 μM (B), 1 μM (C), and 100 μM (D), to determine 
cytotoxicity. Control I/R without CBD treatment is represented by (E). CBD was tested during ischemia, 
0.001 μM (F), 1 μM (G), and 100 μM (H), and during I/R, 0.001 μM (I), 1 μM (J), and 100 μM (K), to determine if 
protection could be stimulated. 
CBD during normoxia 
A) Normoxia  E) I/R 
B) 0.001 μM  F) 0.001 μM I) 0.001 μM  
C) 1 μM  G) 1 μM  
CBD during ischemia and 
reperfusion 
CBD during ischemia only 
J) 1 μM  
D) 100 μM  H) 100 μM  K) 100 μM  
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4.1.1  Average cell viability in percentage according to morphology 
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Figure 4.2 The effect of 0.001 μM, 1 μM, and 100 μM CBD on average cell viability during normoxia only, during 
ischemia only, or throughout ischemia and reperfusion. Data are presented as mean ± SEM, n = 4. 
Cell viability according to morphology can be seen in Figure 4.2. Cell viability during normoxia without 
CBD treatment had a high percentage, 95.00 ± 0.64 %. This was also seen for the normoxic group 
with 0.001 μM CBD (96.00 ± 0.53 %) and 1 μM CBD (95.00 ± 0.66 %). The administration of 100 μM 
CBD was cytotoxic and significantly (p ≤ 0.0001) reduced the cell viability from 95.00 ± 0.64 % to 3.89 
± 0.58 %. Cell viability was also greatly (p ≤ 0.0001) reduced by I/R without CBD treatment to 28.72 ± 
6.41 %. A similar trend was seen for all I/R groups that received CBD compared to the normoxic 
groups, A. None of the CBD concentrations could stimulate protection when compared to I/R without 
CBD treatment.  
Stellenbosch University  https://scholar.sun.ac.za
37 
 
4.1.2  Average R/G fluorescence of JC-1 in percentage as an early apoptosis indicator 
0 0 .0 0 1 1 1 0 0 0 0 .0 0 1 1 1 0 0 0 .0 0 1 1 1 0 0
0
2 0
4 0
6 0
8 0
1 0 0
1 2 0
C B D  t r e a t m e n t  g r o u p s
P
e
r
c
e
n
t
a
g
e
 (
%
)
**** p   0 .0 0 0 1  v s  A
n  =  4
A
I/RN o rm o x ia
M
****
I /R  w ith o u t  C B D
C B D  d u r in g  is c h e m ia
C B D  d u r in g  is c h e m ia  a n d  re p e r fu s io n
 
Figure 4.3 The effect of 0.001 μM, 1 μM, and 100 μM CBD on average R/G fluorescence of JC-1 during 
normoxia only, during ischemia only, or throughout ischemia and reperfusion. Data are presented as 
mean ± SEM, n = 4. 
Figure 4.3 shows the average R/G fluorescence of JC-1 in percentage as an early apoptosis 
indicator. The normoxic group without CBD treatment was defined as 100 % R/G fluorescence, and 
the other groups calculated as a percentage thereof. The R/G percentages for normoxia with 0.001 
μM CBD (95.56 ± 2.99 %) and 1 μM CBD (96.55 ± 2.63 %) were equally high. 100 μM CBD 
significantly (p ≤ 0.0001) reduced the R/G fluorescence percentage from 100 % to 34.45 ± 6.69 %, 
which confirmed cytotoxicity and apoptosis activation. The R/G fluorescence percentage for all I/R 
treatment groups was significantly (p ≤ 0.0001) reduced compared to the normoxic groups, A. None of 
the CBD treatments could oppose the loss of R/G fluorescence percentage to prevent apoptosis. 
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4.2 The effect of per-treatment with PDE5 inhibitor and β-AR stimulation during I/R 
on isolated ventricular cardiomyocytes survival 
Objective 2: 
a) To determine if the inhibition of PDE5 during ischemia protect cardiomyocytes against I/R 
damage. 
b) To determine if the inhibition of PDE5 during ischemia protect cardiomyocytes against 
enhanced I/R damage, driven by general β-ARs stimulation with isoproterenol, or β1-AR 
stimulation with dobutamine. 
c) To determine if, when β2-AR stimulation with formoterol protects cardiomyocytes against I/R 
damage, PDE5 inhibition further enhance protection. 
 
PDE5 was inhibited with 10 μM sildenafil during 20 min ischemia only, to determine if PDE5 activity 
during ischemia is harmful and thereby contributes to I/R injury. In order to investigate the relationship 
between PDE5 and β-AR signaling, PDE5 inhibition during ischemia was also applied together with 
selective β-AR stimulation during I/R. β-ARs were stimulated by the non-selective β-AR agonist, 
isoproterenol (100 nM), the selective β1-AR agonist, dobutamine (10 μM) and the β2-AR agonist, 
formoterol (10 μM), respectively. The concentrations of drugs were obtained from the literature and 
from tests previously done in our laboratory, and representative images for cell viability and R/G 
fluorescence are shown in Figure 4.4. An n = 8 for all treatment groups were analysed, except for the 
non-selective β-AR (isoproterenol) groups, which had an n = 4. For each treatment group two repeats 
per heart were analysed. The isolations yielded an average cell viability of 82 %. 
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Figure 4.4 Representative fluorescence images of isolated ventricular cardiomyocytes per-treated with PDE5 
inhibitor (sildenafil), β1-agonist (dobutamine), β2-agonist (formoterol), and a general βARs-agonist 
(isoproterenol). Ischemia was induced for 20 min, followed by 60 min reperfusion, which included JC-1 staining. 
Normoxic control (A) cells, I/R control (B), I/R with PDE5 inhibitor (C), I/R with β1-agonist (D), I/R with β1-agonist 
and PDE5 inhibitor (E), I/R with β2-agonist (F), I/R with β2-agonist and PDE5 inhibitor (G), I/R with βARs-agonist 
(H), and I/R with βARs-agonist and PDE5 inhibitor (I). 
  
F) I/R + β2 G) I/R + β2 + [PDE5] 
A) Normoxia B) I/R C) I/R + [PDE5] 
D) I/R + β1 E) I/R + β1 + [PDE5] 
I) I/R + βARs + [PDE5] H) I/R + βARs 
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Figure 4.5 The effect of per-treatment with PDE5 inhibitor (sildenafil) and β-AR stimulation during I/R on 
average cell viability. Data are presented as mean ± SEM, β-ARs (isoproterenol) groups had an n = 4 and all 
other groups had n = 8. 
Cell viability according to morphology can be seen in Figure 4.5. Cell viability was significantly (p ≤ 
0.0001) reduced from normoxic control (C), 96.13 ± 0.64 %, to I/R without treatments (0), 12.45 ± 2.55 
%, as was similar for all I/R treatment groups. No significant difference between the different I/R per-
treatment groups were found. None of these per-treatments protected the isolated ventricular 
cardiomyocytes against I/R injury, or enhanced damage. 
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4.2.2  Average R/G fluorescence of JC-1 in percentage as an early apoptosis indicator 
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Figure 4.6 The effect of per-treatment with PDE5 inhibitor (sildenafil) and β-AR stimulation during I/R on 
average R/G fluorescence of JC-1. Data are presented as mean ± SEM, β-ARs (isoproterenol) groups had 
an n = 4 and all other groups had n = 8. 
Figure 4.6 shows the average R/G fluorescence of JC-1 in percentage as an early apoptosis 
indicator. I/R without per-treatment (0) did not indicate apoptosis activation. The average R/G 
fluorescence in percentage for normoxic control (C), 100 %, was significantly (p ≤ 0.01) reduced by I/R 
with β-ARs stimulation, 46.18 ± 5.58 %, and I/R with β-ARs and PDE5 inhibition (β-ARs + [PDE5]), 
45.26 ± 6.46 %. This significant reduction (p ≤ 0.05) was also seen with β2 stimulation during I/R, 
56.82 ± 8.97 %, and I/R with β2 stimulation and PDE5 inhibition (β2 + [PDE5]), 58.74 ± 9.73 %, 
compared to the normoxic control (C), 100 %. There was no significant difference between any I/R 
per-treatment groups compared to I/R without treatment. 
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DISCUSSION 
This study aimed to determine whether the function of PDE5 can regulate cardioprotection or damage. 
This study also aimed to evaluate whether CBD can protect cultured adult cardiomyocytes against I/R 
damage. Additionally the role of PDE5 in protection by CBD was also planned to be tested. 
CBD, during ischemia only and continuously during I/R, and per-treatment with PDE5 could not 
protect the isolated ventricular cardiomyocytes from I/R injury. This was evident in both endpoints, cell 
viability (Figure 4.2 and Figure 4.5) and R/G fluorescence (Figure 4.3 and Figure 4.6), evaluated. 
CBD did not protect isolated ventricular cardiomyocytes against I/R injury 
This was the first study that determined the effect of different CBD concentrations on isolated 
ventricular cardiomyocytes when administered throughout ischemia, or from the start of ischemia and 
for 15 min at the start of 60 min reperfusion. Cardioprotection could not be stimulated with 0.001 μM or 
1 μM CBD, while 100 μM was found to be cytotoxic, as indicated by the decreased cell viability 
(Figure 4.2) and R/G fluorescence (Figure 4.3). 
The activation of CB receptors with cannabinoids was found to stimulate protection against myocardial 
ischemia and can preserve coronary endothelial function (Krylatov et al., 2001; Lasukova et al., 2008; 
Ugdyzhekova et al., 2001). CBD can activate both CB1 and CB2 receptors, at concentration between 
1 μM – 10 μM, and is known to have therapeutic potential (Pertwee, 2008; Thomas et al., 2007), 
possibly by modulating CN levels via Gi coupling, or for CB1 via Gs. It was expected that 1 μM CBD 
should be adequate to activate the CB receptors to stimulate cardioprotection against I/R, via 
increasing cGMP or reducing cAMP levels. 
The limited research done, only 3 in vivo studies, on CBD in the setting of I/R has provided some 
evidence of the potential of CBD as cardioprotective agent, described below. 
Durst and colleagues (2007) found that the hearts from rats that received CBD (5 mg/kg) 1 h before 
ischemia induction, and then again every 24 h for 7 days after ischemia, had a decreased infarct size, 
associated with reduced myocardial inflammation, and reduced IL-6 levels. 
Walsh and colleagues (2010) found that in rat hearts, where CBD was administered, either 10 min 
prior to 30 min of ischemia (10 or 50 μg/kg), or 10 min prior to 2 h of reperfusion (50 μg/kg), was 
cardioprotective by reducing both ventricular arrhythmias and infarct size. 
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Feng and colleagues (2015) experimented on rabbit hearts, where a 90 min coronary artery occlusion 
was followed by 2 intravenous doses (100 mg/kg) of CBD before 24 h reperfusion, and they found 
CBD reduced the infarct size and restored the left ventricular functioning. 
It is possible that a higher concentration CBD, above 1 μM, but below 100 μM to avoid cytotoxicity, 
would be more sufficient to stimulate CB receptors to induce protection in the isolated cardiomyocytes. 
Alternatively, the administration of CBD might be more dependent on the involvement of the immune 
system. Therefore whole heart studies, or isolated cardiomyocyte studies with the co-culturing of other 
cells, including endothelial and immune cells to mimic the immune response in a whole heart, might 
provide a better understanding of the mechanism by which CBD possibly induces protection. 
Per-treatment with PDE5 inhibition did not protect the isolated ventricular cardiomyocytes 
against I/R injury 
PDE5 activity is specific for cGMP hydrolysis, and the inhibition thereof stimulates protection in 
various disorders, including erectile dysfunction, heart failure, pulmonary hypertension, and diabetes 
(Das et al., 2015; Senzaki et al., 2001). 
More importantly, both in vivo (Das et al., 2002; Ockaili et al., 2002; Salloum et al., 2003; Salloum et 
al., 2006) in vitro (Das et al., 2005; Das et al., 2006) studies provide evidence of PDE5 inhibitor as 
protective agent against I/R injury. However, the main focus of these studies was to inhibit PDE5 
activity only prior to ischemia, and not at the onset of ischemia, which was the novel aim of this study. 
We did not find any cardioprotection when PDE5 was inhibited at the start of ischemia, but other 
researchers could induce cardioprotection when PDE5 was inhibited prior to ischemia. There are 
many more articles, but some are explained below. 
Das and colleagues (2005) in a cultured isolated cardiomyocyte study found that, the inhibition of 
PDE5 with 1 μM or 10 μM Sildenafil 1 h prior to 40-min I/1 or 18-h R significantly reduced apoptosis 
and necrosis, with an n = 3. They simulated ischemia with 10 mM 2DG, pH set at 6.2, and N2 gas 
balanced with 1 - 2 % O2 and 5 % CO2. They determined cell viability by visually counting the cells as 
identified by necrosis, trypan blue staining and lactate dehydrogenase (LDH) release, and apoptosis, 
JC-1 staining and terminal deoxynucleotidyl transferase-mediated nick end-labeling (TUNEL) assay. 
In 2008 Das and colleagues followed a similar protocol and found that PDE5 inhibition with 1 μM or 
10 μM Sildenafil 1 h prior to 20-min I/30-min R significantly reduced apoptosis and necrosis, with an 
n = 4. They again determined cell viability by only visually counting the cells as identified by necrosis 
using trypan blue staining, and by apoptosis using the TUNEL assay. For both these experiments, the 
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isolated cardiomyocytes were cultured for only 1 h, compared to the overnight culture protocol used in 
this study. 
It is interesting to note that Das and colleagues did not fix the trypan blue stain. Trypan blue was 
supplemented into the cardiomyocyte plate, and left to develop for ~ 5 min. The stained cells were 
then counted under the microscope and cell viability as a percentage of the total population was 
evaluated. Not fixing the stain could allow for the stain to leak out of the cells, which makes identifying 
the stained necrotic cells difficult. This is only the case with adult cardiomyocytes, because of their 
size and irregular shape, and not when trypan blue is used to stain other, smaller, cells. Trypan blue 
stain was also previously tried in our laboratory, but the stain could not be successfully fixed, and 
when the fixing buffer was removed the stain leaked out of the cells. 
Only one study found that PDE5 inhibition induced cardioprotection when inhibited at the start of 
reperfusion. Salloum and colleagues (2007) inhibited PDE5 at the start of 3 h reperfusion for 65 min, 
after 30 min ischemia, in rabbit hearts. They found that cardioprotection could be stimulated, by a 
similar mechanism as preconditioning with mitochondrial KATP channel opening, and that the infarct 
size was reduced. 
In this study the inhibition of PDE5 with 10 μM sildenafil as per-treatment could not stimulate the 
expected cardioprotection against I/R injury. The involvement of specific β1, β2, and non-specific 
β-ARs with PDE5 inhibition was evaluated, but could also not be identified. None of the β-AR agonists 
had an effect, which is strange, since β1-AR activation leads to cardio damage (Spear et al., 2007) 
and β2-AR activation was found to stimulate cardioprotection (Communal et al., 1999). 
There is a possibility that the drug treatment did not work, and a positive control would have been 
beneficial for this study. Unfortunately, there were not enough funds available to purchase the cGMP 
antibody kit, which is very expensive. Furthermore, when this study originated, research was also 
being done on the inhibition of PDE3 and PDE4 using the same I/R protocol. PDE4 inhibition (with 
10 μM Rolipram) could not stimulate cardioprotection, and PDE3 inhibition (with 10 μM Milrinone) 
stimulated minor cardioprotection, but not significantly. Both PDE3 and PDE4 inhibitors were tested 
with a cAMP assay and the assay proved that the inhibitors could alter cAMP levels.  
The 10 μM sildenafil used in this study is similar to the concentration found in the literature and it was 
expected that PDE5 activity would be blunted to induce cardioprotection. Both β1-AR stimulation with 
dobutamine, to induce damage, and β2-AR stimulation with formoterol, to stimulate protection, did not 
have the desired outcomes. It was also expected that the administration of CBD would result in 
cardioprotection. Subsequently, it is possible that this study had a problem, potentially with the method 
of analysis or with the way the experiments were conducted. The next part of the study focused on 
determining where the problem was. 
Stellenbosch University  https://scholar.sun.ac.za
45 
 
PART 2 
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  CHAPTER 5
Solving the Problems 
No cardioprotection could be elicited with PDE5 inhibition, CBD treatment, or β2-AR (formoterol) 
stimulation, yet all these treatments are known to be cardioprotective. Additionally I/R damage could 
also not be enhanced by β1-AR (dobutamine) stimulation or general β-AR (isoproterenol) stimulation, 
yet these stimuli are known to enhance I/R damage. Thus, none of the drugs used in this study could 
alter I/R damage, which clearly indicates an error in this study. Areas to consider where errors might 
have occurred include the experimental protocol, the method of analysis, or the parameters measured, 
which were addressed in this part of the study. 
5.1 The experimental protocol 
It is possible, but less likely, that there was a problem with the experimental protocol. Average cell 
viability after I/R, for the CBD experiment (Figure 4.2), was reduced from 95.95 ± 1.27 % to 
28.72 ± 18.13 %, and for the PDE5 experiment (Figure 4.5), from 96.13 ± 1.80 % to 12.45 ± 2.55 %. 
The average R/G fluorescence for the CBD experiment (Figure 4.3) was also significantly reduced 
from 100 % to 15.07 ± 16.85 %. 
Nonetheless, previous experiments in our laboratory found that, with the same ischemic buffer 
combination, formoterol could induce cardioprotection. Furthermore, the 10 mM SDT used in this 
study to induce acute ischemia correlates with the range found in literature, 0.5 – 10 mM 
(Chanoit et al., 2008; Ruiz-Meana et al., 2011; Wei et al., 2007; Yeung et al., 2007). Although, the 
ischemic buffer with 10 mM SDT was applied for only 10 min (Yeung et al., 2007), while it was applied 
for 20 min in our study. Therefore, the 20 min ischemic period might have been too long. The 
concentration of 3 mM 2DG is lower compared to the range found in literature, 10 – 20 mM 
(Cao et al., 2005; Hu et al., 2008), and it is not expected that the 3 mM 2DG would induce harsh 
injury. 
5.2 The method of analysis 
It is possible that the error was with the program used for analysis, Image J (Schneider et al., 2012), 
and another image analysis program could provide different results, which was tested in this part of 
the study. 
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5.3 The parameters measured 
The standard method used to evaluate viability or injury of isolated cardiomyocytes is according to 
morphology, and was used to determine cell viability for Figure 4.2 and Figure 4.5. Morphology 
analysis classifies rod shaped cells as viable and round shaped cells as non-viable, and is generally 
used to define injury in terms of cell viability percentage. 
It is with rod and round classification where the error possibly was. The same cell could be classified 
as either rod or round by different researchers, depending on the researcher’s personal interpretation. 
In an injured cell population the cells cannot always clearly be distinguished as rod or round shaped 
as can be seen below in Figure 5.1 with C and D. With I/R, explained in section 1.2, the dynamics of 
cardiomyocytes are effected through a cascade of molecular, biochemical, and morphological 
changes (Buja, 2005). The healthy rod shaped cells become shortened and box shaped, and with 
further injury or reperfusion they become round, hypercontracted, and cellular function is lost 
(Figure 5.1) (Abdallah et al., 2006; Boston et al., 1998; Bowers et al., 1992). 
 
 
Figure 5.1 A) Fluorescence image of an injured hypoxic population. With I/R, viable rod shaped cells (B) 
become box shaped (C), and with further injury or reperfusion they can become round, hypercontracted, (D) and 
lose cellular function.   
 
It is important to remove the human aspect when analysing the images to produce clear and 
consistent results. Therefore, a gold standard or criteria is necessary whereby analysis should be 
done. 
B D C 
D 
C 
B 
A 
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Although, less popular, morphometry analysis can be used to separate the viable rods from non-viable 
round cells, also to evaluate cell viability percentage. Morphometry analysis is based on measuring 
the length and width of cells and is expressed as a ratio (L/W). Geisbuhler and colleagues (2002) used 
L/W to characterize adult rat cardiomyocytes, with L/W > 8 as viable cells, cells with an L/W of 1.5 – 8 
as in contracture but still viable, and cells with L/W < 1.5 as hypercontracted round cells that were 
non-viable. Another research group, Boston and colleagues (1998) also used L/W to separate the rod 
and round cells, but here they used adult rabbit cardiomyocytes which are bigger than rat 
cardiomyocytes, and considered L/W < 3 as hypercontracted cells. L/W can measure the degree of 
contracture/hypercontracture for a cardiomyocyte population, which cannot be done with morphology 
analysis. 
It is noteworthy that cardiomyocyte length is often measured in single cardiomyocyte experiments to 
evaluate contracture (Louch et al., 2011; Webster et al., 2012), but has not yet been used to separate 
rod and round cells. It is possible that length can report similar information about the injured 
cardiomyocyte population as L/W, and will take half of the manual analysis time. 
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  CHAPTER 6
Hypothesis, Aims and Objectives 
6.1 Hypothesis 
We hypothesize that the experimental error was not with the analysis program, but with the 
parameters measured, where morphology analysis provides unreliable results, and morphometry 
analysis provides impartial results. 
6.2 Aims 
The first aim of Part 2 of this study was to compare the results from ImageJ analysis with the results 
from another image analysis program. 
The second, but main aim, was to compare morphology analysis with morphometry analysis to 
determine if morphology is biased. For this aim it was important to quantify length of hypercontracted 
cardiomyocytes, see objective 3 below. Quantifying length will enable its use as morphometry 
measurement, to measure the average contraction of the population, and to sort the rod from the 
round cells. 
6.3 Objectives 
1. To evaluate if ImageJ analysis and another image analysis program (CellProfiler) provide similar 
results. 
2.  To determine whether similar values of R/G fluorescence and cell length can be calculated from 
the cell area selected by cell shape outline, compared to a straight line selection along the cell 
length. 
3. To determine the average length of round hypercontracted cells, in order to sort non-viable from 
viable cardiomyocytes based on cell length. 
4. a) To compare the average cell viability determined by morphology and morphometry 
measurements 
  to establish whether morphology provides biased results. 
 b) To evaluate the average R/G fluorescence, cell length and L/W ratio of the viable population 
selected by morphology and morphometry, to characterize the viable population. 
5. To re-evaluate the CBD and PDE5 inhibition data from Part 1 using morphometry analysis. 
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To achieve objectives 1 – 4 I/R and H/R will be induced to compare the results between three different 
conditions: normoxia, I/R and H/R.  
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  CHAPTER 7
Materials and Methods 
The same protocols provided in Chapter 3 for isolating and culturing cardiomyocytes and for data 
collection were followed.  
7.1 I/R, H/R and JC-1 staining 
Cardiomyocytes were washed (x 3) for 30 min with modified M199 culture buffer (without blebbistatin), 
followed by ischemia or hypoxia. Ischemia was induced for 60 min by ischemic wash (refer to 
section 3.6) with 5 mM 2DG and 5 mM SDT (Figure 7.1). Hypoxia was induced for 60 min by ischemic 
wash with 10 mM 2DG and 100 % N2 gas (Figure 7.1). Ischemia and hypoxia were followed by 60 min 
reperfusion with modified M199 culture buffer (without blebbistatin), which included 15 min incubation 
with 15 μM JC-1 stain, two washes and 30 min stain development, before images were captured. 
Normoxic cells received the same number of buffer changes as I/R or H/R, followed by JC-1 staining. 
 
 
Figure 7.1 Protocol for 60 min simulated ischemia (5 mM 2DG and 5 mM SDT) or hypoxia (10 mM 2DG and 100 
% N2 gas), followed by 60 min reperfusion, which included 15 min JC-1 stain. 
7.2 Data analysis 
ImageJ (Schneider et al., 2012) and CellProfiler (Kamentsky et al., 2011) freeware were used for 
image analysis to compare the two analysis programs. ImageJ was used for image analysis for 
ischemia and hypoxia experiments. The “freehand tool” was selected and used to manually draw the 
shape outlines (A on Figure 7.2) of the cells, the fluorescence and the length of the cells measured. 
Cell length was measured by measurement of a straight line drawn along the cell length (A on 
Figure 7.2), and by feret measurement. Feret is a measure of the distance of the two furthest points of 
Ischemia: Ischemic wash with  
5 mM 2DG + 5 mM SDT 
Hypoxia: Ischemic wash with  
10 mM 2DG + 100 % N2 gas 
Modified M199 culture buffer 
Overnight 
culture 
  Min 
  120   90   75   60 -30 
Ischemia or Hypoxia Reperfusion JC-1 stain 
  0 
 Stabilization  Stain development 
Microscope 
Data 
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a cell and is determined by ImageJ, which automatically draws a virtual rectangle around the selected 
shape outline (A on Figure 7.2). Straight line was also used for L/W measurement, by drawing a 
straight line across the length and width of the cell (C on Figure 7.2). 
 
 
 
Figure 7.2 A) Shape outline is drawn, indicated by the white outline, and ImageJ evaluates cell length with the 
feret measurement, indicated by the red rectangle B) Straight line is drawn, indicated by the yellow line, to 
measure cell length C) Straight line is drawn, indicated by the white line, to measure cell length and width. 
7.3 Statistics 
Data are presented as mean ± SEM. GraphPad Prism® 6 was used for graph plotting and analysis 
done with one-way analysis of variance (ANOVA) multiple comparison and Bonferonni post hoc test. 
p ≤ 0.05 was considered to be statistically significant. 
Due to the complexity of the comparisons, differences between groups were indicated with different 
letters of the alphabet, for example A versus B. If groups were similar and no difference exist, then 
they would either have at least one letter that is the same, for example A versus A, or A versus AB. 
 
C B A 
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  CHAPTER 8
Results 
8.1 A comparison between ImageJ and CellProfiler analysis 
Data from 20-min I/60-min R (Figure 4.6) for ImageJ (n = 8) were compared with re-evaluated data 
from CellProfiler (n = 4). The isolations had an average cell viability of 82 %. 
Objective 1: 
To evaluate if ImageJ analysis and another image analysis program (CellProfiler) provide similar 
results. 
8.1.1 Average R/G fluorescence of JC-1 in percentage as an early apoptosis indicator: 
ImageJ versus CellProfiler 
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Figure 8.1 A comparison between CellProfiler and ImageJ analysis: the effect of per-treatment with PDE5 
inhibitor, β1, and β2 stimulation during I/R on average R/G fluorescence. Data are presented as mean ± SEM, 
n = 4 for CellProfiler; n = 8 for ImageJ. 
Figure 8.1 shows that there was no significant difference between CellProfiler and ImageJ analysis for 
all of the per-treatment groups. The two analysis programs provided similar results, and therefore the 
original results from ImageJ were accurate.  
llProfiler n = 4 
ImageJ n = 8 
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8.2 A comparison between morphology and morphometry analysis 
Data from normoxic, 1-h I/60-min R and 1-h H/60-min R were compared for 8 hearts (n = 8), with two 
repeats per heart. The isolations yielded an average cell viability of 75 %. 
Objective 2: 
To determine whether similar values of R/G fluorescence and cell length can be calculated 
from the cell area selected by cell shape outline, compared to a straight line selection along the 
cell length. 
The cell shape outline is drawn to measure the R/G fluorescence for the total cell area. It is not clear if 
drawing a straight line can provide similar results as drawing the outline of the cell. Cell shape outline 
was used to measure the R/G fluorescence for the CBD (Figure 4.3) and PDE5 (Figure 4.6) 
experiments. The straight line measurement is used to measure the length of a cell. The shape outline 
can also be used to measure the length of a cell, given as the feret measurement 
(refer to Figure 7.2 A and B). Drawing the cell shape outline is a time consuming process, whereas 
drawing a straight line would be much simpler. Thus if the straight line can evaluate R/G fluorescence 
accurately, it would reduce the time analysis takes. 
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8.2.1 Average cell length and R/G fluorescence measured from cell shape outline (cell 
area) and straight line 
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Figure 8.2 The average R/G fluorescence for normoxia, ischemia and hypoxia as identified by cell shape outline 
(cell area) and straight line. Data are presented as mean ± SEM, n = 8. 
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Figure 8.3 The average cell length for normoxia, ischemia and hypoxia as identified by cell shape outline (cell 
area) and straight line. Data are presented as mean ± SEM, n = 8. 
Average R/G fluorescence, refer to Figure 8.2, by cell shape for normoxia, A: 1.19 ± 0.17, was 
significantly higher than ischemia, C: 0.25 ± 0.02 (p ≤ 0.0001), and hypoxia, B: 0.66 ± 0.08 (p ≤ 0.05). 
The same trend was seen with straight line measurement, where R/G fluorescence for ischemia, C: 
0.24 ± 0.02 (p ≤ 0.0001), and hypoxia, B: 0.65 ± 0.08 (p ≤ 0.05), were significantly lower than 
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normoxia, A: 1.15 ± 0.17. No significant difference was found between cell shape outline and straight 
line. 
Average cell length, refer to Figure 8.3, according to cell shape for ischemia, A: 59.43 ± 1.39 μm 
(p ≤ 0.0001), and hypoxia, B: 67.43 ± 2.52 μm (p ≤ 0.01), were significantly reduced compared to 
normoxia, 84.37 ± 4.37 μm. Cell length as quantified by straight line provided similar results, where the 
averages for ischemia, A: 55.28 ± 1.06 μm (p ≤ 0.0001), and hypoxia, B: 62.93 ± 2.41 μm (p ≤ 0.01), 
were significantly shorter than normoxia, 80.14 ± 4.67 μm. No significant difference was found 
between cell shape outline and straight line. 
The results from average R/G fluorescence, Figure 8.2, and average cell length, Figure 8.3, indicate 
that drawing a straight line across the cardiomyocytes is as sufficient and accurate as cell outline, but 
is less time consuming.  
Straight line measurement was used to achieve Objective 3, 4 and 5. 
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Objective 3: 
To determine the average length of round hypercontracted cells, in order to sort non-viable 
from viable cardiomyocytes based on cell length. 
Length has never been used to evaluate cell viability in a total cell population, and had to be 
characterized. For the normoxic population, morphology selection was used to sort the rod and the 
round cells from each other. The average cell length for the entire rod shaped cells and the entire 
round shaped cells were calculated. 
8.2.2  Separating the viable rods and non-viable round cells according to length 
R o d R o u n d
0
5 0
1 0 0
1 5 0
L
e
n
g
t
h
 (

m
)
****
* * * *  p   0 .0 0 0 1
n  =  8
 
Figure 8.4 Average length of rod and round cells during normoxia. Data are presented as mean ± SEM, n = 8. 
Figure 8.4 shows the average cell length for rod and round shaped cells in a normoxic population. 
The average cell length for the round cells were significantly (p ≤ 0.0001) shorter than the rod cells. 
The round cells were consistently below 55 μm, and thus cells above 55 μm can be considered viable, 
although in an injured population these viable cells will exhibit different degrees of contracture. 
Length ≥ 55 μm was selected as morphometry measurement to identify viable cardiomyocytes in 
Objective 4. 
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Objective 4: 
a) To compare the average cell viability determined by morphology and morphometry 
measurements, to establish whether morphology provides biased results. 
b) To evaluate the average R/G fluorescence, cell length and L/W ratio of the viable population 
selected by morphology and morphometry, to characterize the viable population. 
To determine if morphology selection provides biased results, the viable population, as selected by 
morphology (rod shape) and as selected by morphometry (length ≥ 55 μm and L/W ≥ 1.5), was 
compared. Average cell viability as identified by morphology and morphometry was evaluated first. 
The selected viable population was then assessed according to R/G fluorescence, cell length and L/W 
ratio to identify any differences between morphology and morphometry. It is possible that PDE5 
inhibition and CBD administration did stimulate cardioprotection, but morphology (rod shape) selection 
simply could not detect it. Length ≥ 55 μm has never been used as morphometry measurement to 
evaluate a total cell population, and it is unclear if it can provide similar results to L/W ≥ 1.5. 
Length ≥ 55 μm and L/W ≥ 1.5 might also differ in sensitivity, which needs to be determined. 
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8.2.3 Average cell viability: comparing morphology (rod shape) with morphometry 
(length ≥ 55 μm and L/W ≥ 1.5) analysis 
Cell viability is a very informative parameter and can immediately provide information on the quality of 
the cells, either before, during, or after an experiment. However, it is not known whether viability 
determined by cell shape selection of viable cells provide similar results as morphometric selection. 
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Figure 8.5 Average cell viability of adult cardiomyocytes after normoxia, I/R and H/R. The viable cells were 
selected by rod shape, length ≥ 55 μm and L/W ≥ 1.5. The different letters indicate significant differences 
between treatment groups, and differences between the different methods of analysis within the same treatment. 
Data are presented as mean ± SEM, n = 8. 
Average cell viability, as can be seen in Figure 8.5, for rod shape was significantly (p ≤ 0.0001) higher 
for normoxia, A: 45.62 ± 6.11 %, than for I/R, C: 7.57 ± 1.95 %. The viability of cells with a length ≥ 55 
µm and L/W ≥ 1.5 were significantly (p ≤ 0.001) higher for normoxia, B: 67.78 ± 4.37 % and 79.35 ± 
2.26 %, compared to I/R, D: 41.95 ± 3.41 % and 51.41 ± 3.93 %, respectively. Rod shape, length ≥ 55 
μm, and L/W ≥ 1.5 showed no significant difference between H/R and normoxia. No differences were 
found between normoxia and H/R for any of the selection methods. 
Rod shape, length ≥ 55 μm and L/W ≥ 1.5 were compared within normoxia, I/R, and H/R. For 
normoxia, cell viability was significantly lower for rod shape, A: 45.62 ± 6.11 %, compared to 
length ≥ 55 μm, B: 67.78 ± 4.37 (p ≤ 0.01), and L/W ≥ 1.5, B: 79.35 ± 2.26 % (p ≤ 0.001). The same 
was found for I/R and H/R, where rod shape (I/R: C, 7.57 ± 1.95 %, and H/R: AC, 21.78 ± 4.70 %) was 
significantly lower than length ≥ 55 μm (I/R: D, 41.95 ± 3.41 %, and H/R: BD, 52.08 ± 3.94 %; 
both p ≤ 0.001) and L/W ≥ 1.5 (I/R: D, 51.41 ± 3.93 %, and H/R: BD 70.03 ± 2.38 %; both p ≤ 0.0001). 
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For all conditions was cell viability for rod shape significantly lower than for length ≥ 55 μm and 
L/W ≥ 1.5. These results indicate that morphology selection provided different results compared to 
morphometry selection, and therefore morphology might be biased. No differences were seen 
between the two morphometric methods, indicating that length ≥ 55 μm and L/W ≥ 1.5 are equally 
reliable when assessing cell viability. 
8.2.4  Average R/G fluorescence, cell length and L/W ratio of the viable population 
It was important to characterize the viable population as selected by morphology and morphometry in 
order to determine whether there are any differences between these selected populations. Therefore 
the average R/G fluorescence, cell length and L/W ratio was determined for the cardiomyocytes 
selected by morphology and morphometry. 
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Figure 8.6 Average R/G fluorescence of adult cardiomyocytes after normoxia, I/R and H/R. The viable cells were 
selected by rod shape, length ≥ 55 μm and L/W ≥ 1.5. The different letters indicate significant differences 
between treatment groups, and differences between the different methods of analysis within the same treatment. 
Data are presented as mean ± SEM, n = 8. 
Figure 8.6 show that the average R/G fluorescence for rod shape was significantly (p ≤ 0.0001) 
reduced after I/R, B: 0.39 ± 0.10, compared to normoxia, AD: 1.58 ± 0.17. Similarly, the R/G 
fluorescence of cells with a length ≥ 55 µm and L/W ≥ 1.5 were significantly reduced after I/R, B: 0.24 
± 0.02 (p ≤ 0.0001) and 0.25 ± 0.01 (p ≤ 0.001), compared to normoxia, AD: 1.32 ± 0.18 and 1.30 ± 
0.21, respectively. There were no significant differences found between normoxia and H/R. 
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The comparison between rod shape, length ≥ 55 μm and L/W ≥ 1.5 per treatment condition, showed 
no difference for normoxia and I/R. However with H/R, the R/G fluorescence for rod shape, AC: 
1.67 ± 0.15, was significantly (p ≤ 0.01) higher than both length ≥ 55 μm, BD: 0.82 ±0.13, and 
L/W ≥ 1.5, BD: 0.89 ± 0.15. 
For length ≥ 55 μm and L/W ≥ 1.5, no significant difference could be detected between these two 
methods for normoxia, I/R and H/R, indicating that both morphometry measurements provide similar 
data. Yet, rod shape did not follow a similar trend in all the conditions, which suggests that morphology 
selection is not consistent and could provide misleading results under certain conditions. 
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Figure 8.7 Average cell length of adult cardiomyocytes after normoxia, I/R and H/R. The viable cells were 
selected by rod shape, length ≥ 55 μm and L/W ≥ 1.5. The different letters indicate significant differences 
between treatment groups, and differences between the different methods of analysis within the same treatment. 
Data are presented as mean ± SEM, n = 8. 
Average cell length, as can be seen in Figure 8.7, for rod shape was significantly (p ≤ 0.0001) 
reduced after I/R, B: 70.67 ± 9.87 μm, compared to normoxia, A: 111.50 ± 3.04 μm. Cell length for 
cells with length ≥ 55 μm and L/W ≥ 1.5 was significantly reduced after I/R, B: 67.95 ± 1.05 μm and 
59.61 ± 1.77 μm (both p ≤ 0.001), and H/R, B: 76.44 ± 3.54 µm and 67.73 ± 3.14 μm (both p ≤ 0.05), 
compared to normoxia, A: 95.55 ± 3.99 µm and 87.66 ± 5.00 μm, respectively. Rod shape, 
length ≥ 55 μm and L/W ≥ 1.5 per condition were compared. For normoxia, rod shape, A: 111.50 ± 
3.05 μm, had a significantly (p ≤ 0.01) higher cell length than L/W, C: 87.66 ± 5.00 μm. No differences 
were found for I/R, but for H/R a significantly lower length was found for both length ≥ 55 μm, B: 76.44 
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± 3.54 μm (p ≤ 0.001), and L/W ≥ 1.5, B: 67.73 ± 3.14 μm (p ≤ 0.0001), compared to rod shape, A: 
105.60 ± 2.60 μm. 
Rod shape selection indicated a significant reduction in cell length after I/R compared to normoxia, but 
not for H/R. However, when length ≥ 55 μm and L/W ≥ 1.5 as selections were used, a significant 
reduction in cell length was found for I/R and H/R versus normoxia. Thus length ≥ 55 μm and 
L/W ≥ 1.5 accounted for differences between normoxia and H/R, which rod shape selection could not 
detect. 
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Figure 8.8 Average L/W ratio of adult cardiomyocytes after normoxia, I/R and H/R. The viable cells were 
selected by rod shape, length ≥ 55 μm and L/W ≥ 1.5. The different letters indicate significant differences 
between treatment groups, and differences between the different methods of analysis within the same treatment. 
Data are presented as mean ± SEM, n = 8. 
Figure 8.8 show that Rod shape selection indicated that L/W was significantly (p ≤ 0.001) reduced 
with I/R, B: 2.36 ± 0.38, compared to nomoxia, AC: 4.21 ± 0.15. For cells with length ≥ 55 μm, L/W 
was significantly (p ≤ 0.01) higher for normoxia, AC: 3.40 ± 0.20, compared to I/R, B: 2.32 ± 0.38. L/W 
for cells defined by L/W ≥ 1.5 showed no significant difference when I/R and H/R were compared to 
normoxia. When the three selections were compared per condition, the only differences were found for 
H/R, where rod shape, C: 4.61 ± 0.60, had a significant higher L/W ratio than length ≥ 55 μm, AB: 
2.71 ± 0.22 (p ≤ 0.001), and L/W ≥ 1.5, AB: 2.63 ± 0.17 (p ≤ 0.0001). 
The length ≥ 55 μm selection accounted for a differences between normoxia and I/R, which could not 
be detected by L/W ≥ 1.5 selection, and thus length ≥ 55 μm can be considered a more sensitive 
measurement. The fact that there is such a big difference between morphology and morphometry data 
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with H/R for R/G fluorescence and cell length indicated that rod shape selection is unreliable. 
Morphometry analysis is objective and is not influenced by the personal interpretation of the 
researcher. 
8.3 The effect that different CBD concentrations exert during normoxia, ischemia 
and I/R on isolated ventricular cardiomyocytes survival 
Objective 5: 
Re-evaluate the CBD and PDE5 inhibition data from Part 1 using morphometry analysis. 
Given that rod shape selection of viable cells seems to be inconsistent and thus unreliable, it is very 
possible that the cell viability data analysed by morphology in Part 1 (Figure 4.2 and 4.5) of this study 
are incorrect. Therefore the images collected for CBD treatments during normoxia, ischemia, and I/R, 
and for PDE5 inhibition as per-treatment were re-evaluated using morphometry, more specifically cell 
length. The reason for using length instead of L/W is because it takes less time and appeared to be 
more sensitive in finding differences than L/W (Figure 8.8). The average cell length was measured 
because it can report whether contracture/hypercontracture injury was induced (Figure 8.9 and 
Figure 8.11). The cell viability data were also re-evaluated (Figure 8.10 and Figure 8.12) with 
length ≥ 55 μm and compared to the original morphology result (Figure 4.2 and Figure 4.5), which 
possibly provided untruthful results. 
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8.3.1  Average cell length in microns as indicator of contracture 
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Figure 8.9 The effect of 0.001 CBD, 1 CBD, and 100 μM CBD on average cell length during normoxia and I/R. 
CBD was administered during ischemia only or continuously during I/R. Data are presented as mean ± SEM, 
n = 4. 
Figure 8.9 show average cell length in microns as indicator of contracture. The average cell length for 
normoxia without CBD treatment was 113.30 ± 2.18 μm. Similar averages were found for the normoxic 
group with 0.001 μM CBD (109.80 ± 2.25 μm) and 1 μM CBD (110.40 ± 2.59 μm). 100 μM CBD during 
normoxia was cytotoxic as seen by the significantly (p ≤ 0.0001) reduced cell length of 52.88 ± 1.38 
μm compared to the normoxic groups, A. The same significant (p ≤ 0.0001) reduction in cell length 
was seen for all I/R treatment groups compared to the normoxic groups, A. None of the CBD 
treatment groups could prevent contracture. 
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8.3.2  Average cell viability in percentage: to compare morphology and length ≥ 55 μm 
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Figure 8.10 A comparison between morphology and length ≥ 55 μm: the effect of 0.001 CBD, 1 CBD, and 
100 μM CBD on average cell viability during normoxia and I/R. CBD was administered either during ischemia 
only or continuously during I/R. Data are presented as mean ± SEM, n = 4. 
Average cell viability, as can be seen on Figure 8.10, for I/R without CBD treatment (0) was 
significantly (p ≤ 0.001) lower according to morphology, 28.72 ± 6.41 %, than length ≥ 55 μm, A: 60.24 
±. 2.98 %. Cell viability was not significantly increased by length ≥ 55 μm for any other CBD treatment 
group. No significant difference between all I/R CBD treatment groups compared to I/R without CBD 
(0) could be found for length ≥ 55 μm selection.  
Length ≥ 55 μm did not provide more information about the CBD treatment groups than morphology, 
and none of the CBD treatment groups stimulated protection against I/R injury. 
However, the error bars for length ≥ 55 μm was smaller compared to the error bars for morphology. 
This indicated that the selections made by length ≥ 55 μm were closer in values, the repeats were 
more similar, than the repeats selected by morphology. 
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8.4 The effect of per-treatment with PDE5 inhibitor and β-AR stimulation during I/R 
on isolated ventricular cardiomyocytes survival 
8.4.1  Average cell length in microns as indicator of contracture 
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Figure 8.11 The effect of per-treatment with PDE5 inhibitor and β-AR stimulation during I/R on average cell 
length. Data are presented as mean ± SEM, β-ARs groups (isoproterenol) had an n = 4 and all other groups had 
n = 8. 
The average cell length in microns as indicator of contracture can be seen in Figure 8.11. There was 
a significant difference (p ≤ 0.0001) between the normoxic control (C) and I/R without per-treatment 
(0), where cell length was decreased from 115.10 ± 1.39 μm to 64.44 ± 2.37 μm. This was also found 
for all I/R per-treatment groups, with no significant difference between them. 
None of these per-treatments stimulated protection against I/R injury. 
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8.4.2  Average cell viability in percentage: to compare morphology and length ≥ 55 μm 
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Figure 8.12 A comparison between morphology and length ≥ 55 μm: the effect of per-treatment with PDE5 
inhibitor, β1, and β2 stimulation during I/R on cell viability. Data are presented as mean ± SEM, n = 8. 
Figure 8.12 show the average cell viability in percentage: to compare morphology and length ≥ 55 μm. 
Length ≥ 55 μm selection significantly (p ≤ 0.0001) increased average cell viability for all I/R treatment 
groups compared to morphology. However, no significant difference between any I/R treatment group 
compared to I/R without treatment (0) could be found when length ≥ 55 μm was used as 
measurement. Although the average cell viability for all I/R treatment groups were increased by length 
≥ 55 μm selection, it could not provide more information than morphometry. Per-treatment with PDE5 
inhibitor did not protect the isolated ventricular cardiomyocytes against I/R injury. 
Re-evaluating the cell viability data with length ≥ 55 μm as selection for the CBD treatment and PDE5 
inhibition experiments did not provide more information than morphology selection, and none of these 
treatments could induce cardioprotection. 
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DISCUSSION 
Part 2 of this study focused on finding a reason why no protection could be elicited with PDE5 
inhibition and CBD treatment in cultured adult cardiomyocytes, evaluating if the error was with the 
image analysis program or with the parameters measured. 
There is a possibility that the error was with the experimental protocol previous experiments in our 
laboratory found that, with the same ischemic buffer combination, formoterol could induce 
cardioprotection. The 3 mM 2DG and 10 mM SDT also correlates with the concentration ranges found 
in the literature (Hu et al., 2008; Ruiz-Meana et al., 2011; Yeung et al., 2007). Accordingly, it was first 
determined if the error was with the analysis program and thereafter with the parameters measured. 
PDE5 inhibition and the administration of CBD did not induce cardioprotection in this study. No 
research has been done on PDE5 inhibition as per-treatment or on the effects of CBD on cultured 
isolated cardiomyocytes. The novelty of this study made comparing the results found to the results in 
the literature impossible, where cardioprotection with PDE5 inhibition was induced by treatment prior 
to ischemia (Ahmad et al., 2009; Bremer et al., 2005; Das et al., 2002; Das et al., 2009; 
du Toit et al., 2005; Kukreja et al., 2005; Ockaili et al., 2002; Salloum et al., 2003; Salloum et al., 2006; 
Sesti et al., 2007). The literature provides evidence that β1-AR stimulation increases I/R damage 
(Spear et al., 2007) and β2-AR stimulation induces protection (Communal et al., 1999), but this was 
also not found in this study.  
ImageJ is a reliable open-source analysis program 
The first aim of Part 2 of this study was to determine if the original R/G fluorescence results from 
ImageJ analysis (Figure 4.6) were reliable. The results from ImageJ (Schneider et al., 2012) analysis 
were compared to the results from CellProfiler (Kamentsky et al., 2011) (Figure 8.1). Both programs 
are open-source freeware and can easily be downloaded from the internet. There was no significant 
difference between the results from the two programs. The R/G fluorescence results from ImageJ 
analysis are thus trustworthy. 
Morphology analysis is biased, whereas morphometry analysis is reliable 
The parameters, cell viability and R/G fluorescence intensity, were evaluated in Chapter 4 to 
determine the degree of damage or survival of cardiomyocytes. 
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For cell viability assessments (Figure 4.2 and Figure 4.5) morphology analysis was used, where cells 
were identified as either rod or round, and was presented as the percentage viable cells in the total 
population. But there is a discrepancy when morphology analysis was used, for the reason that in an 
injured population it is difficult to separate rod and round shaped cells (Figure 7.2). This could mean 
that different researchers would classify the same cell either as rod, or as round, depending on 
personal justification, indicating that morphology measurement could be biased (Figure 8.5 – 8.8). 
Straight line measurement is as accurate as cell shape outline to measure the R/G 
fluorescence of a cardiomyocyte population 
R/G fluorescence intensity per cell area was measured by drawing the shape outline and the average 
R/G fluorescence for the cardiomyocyte population (Figure 4.3 and Figure 4.6) was then determined. 
Drawing the shape outline for the total cell population per image is a time consuming process. Straight 
line measurement can be used to measure the length of a single cell, and when straight line was used 
for analysis it also seemed to accurately measure the R/G fluorescence of the cell. However, the use 
of cell length as a measurement of R/G fluorescence for a total population has never been quantified. 
Therefore average R/G fluorescence (Figure 8.2) and cell length (Figure 8.3) for the normoxic, 
ischemic and hypoxic populations, were measured by the straight line measurement and the shape 
outline measurement to determine if both measurements provided similar results. 
There was no significant difference between the cell shape outline measurement and the straight line 
measurement. Straight line measurement can be used to not only evaluate the cell length and R/G 
fluorescence of a single cardiomyocyte, but could evaluate the total cardiomyocyte population. 
Straight line measurement is thus a quicker, more effective, measurement than shape outline. 
Length could be quantified to be used as morphometry measurement 
The straight line measurement is versatile and could measure average R/G fluorescence and 
contracture/hypercontracture for an injured population, but could not identify the percentage of 
contracted cells in the population. Therefore, Part 2 of this study aimed to enable the use of length as 
a morphometry measurement, by sorting the rod and the round shaped cells according to length. 
Morphology analysis was used to separate the rod from the round shaped cells and the average cell 
length for the rods and the rounds was determined. 
Figure 8.4 found that rod shaped cells were consistently above 55 μm, whereas round shaped cells 
were consistently below 55 μm. It is important to note that the viable cells, above 55 μm, will exhibit 
varying degrees of contracture in an injured population. Length ≥ 55 μm was selected as morphometry 
Stellenbosch University  https://scholar.sun.ac.za
70 
 
measurement to identify viable cells in a cardiomyocyte population, which could then be presented as 
percentage cell viability. 
Both length ≥ 55 μm and L/W ≥ 1.5, previously used by Geisbuhler and colleagues (2002) to 
characterize viable adult cardiomyocytes, can thus measure the degree of 
contracture/hypercontracture for a cardiomyocyte population, which cannot be done with morphology 
analysis. 
Morphology analysis is biased, morphometry analysis is reliable 
The second aim of Part 2 of this study was to determine if morphology analysis, with rod shaped 
selection, produced biased results compared to morphometry analysis, with the selections 
length ≥ 55 μm and L/W ≥ 1.5. 
Average cell viability, as identified by morphology and morphometry, for the normoxic, ischemic and 
hypoxic populations was evaluated first (Figure 8.5). For all three experimental conditions, the cell 
viability according to morphology selection was significantly lower compared to when morphometry 
selection was used. This indicates that when morphology selection was used, fewer cells were 
selected and the researcher was stricter with the quality of cells selected, whereas both morphometry 
selections were more lenient and included more cells. Length ≥ 55 μm and L/W ≥ 1.5 provided similar 
results. 
The quality of the cells selected, presented by the average cell viability, was evaluated with regards to 
R/G fluorescence, cell length and L/W ratio. 
The R/G fluorescence intensity (Figure 8.6) for the cells selected by morphology was similar for 
normoxia and hypoxia, whereas with morphometry selection the R/G fluorescence for the normoxic 
population was significantly higher than for hypoxia. This means that the few cells selected by 
morphology for each of the three experimental conditions, derived from the cell viability (Figure 8.5), 
had a similar R/G fluorescence intensity. Morphometry accounted for differences between normoxia 
and hypoxia, unlike morphology. 
Average cell length (Figure 8.7) for the hypoxic population found that the cells selected by 
morphology were significantly longer in length than the cells selected by morphometry. Again, with 
morphology selection, no significant difference in cell length was found when normoxia was compared 
to hypoxia, but a significant difference was found when the morphometry selections were used. 
Interestingly, for the average L/W (Figure 8.8), the selection length ≥ 55 μm identified a significant 
reduction in average L/W for ischemia compared to normoxia, which was not found when the selection 
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L/W ≥ 1.5 was used. The conclusion can be made that length ≥ 55 μm is more sensitive than 
L/W ≥ 1.5. 
For average R/G fluorescence (Figure 8.6) and cell length (Figure 8.7), the morphometry selections 
accounted for significant differences between normoxia and hypoxia that morphology selection could 
not detect. Morphometry selection is thus more sensitive and reliable than selection with morphology 
and could account for differences between experimental conditions. Morphology was repetitively 
proven to be biased, by selecting only a few cells (Figure 8.5) that have a high R/G fluorescence 
(Figure 8.6) and do not show any contracture/hypercontracture injury (Figure 8.7 and 8.8). 
Length ≥ 55 μm was found to be a more sensitive measurement than L/W ≥ 1.5. 
The administration of CBD and PDE5 inhibition could not protect the isolated cardiomyocytes 
against I/R damage 
The average cell length for the CBD (Figure 8.9) and PDE5 (Figure 8.11) experiments were 
evaluated, but cardioprotection was not found. The morphometry selection Length ≥ 55 μm was then 
used to re-evaluate the cell viability images for the CBD and PDE5 inhibition experiments. The results 
were compared to the original cell viability results where morphology selection was used (Figure 8.10 
and Figure 8.12). Length ≥ 55 μm selection increased the overall cell viability for all of the ischemic 
groups, but no significant difference between ischemia and any of the treatment groups was found. 
Cardioprotection was not induced. The only possible explanation was that the error of the study was 
with the experimental protocol, where the ischemia induced was too harsh. 
Ischemia induced irreversible damage, whereas hypoxia induced unsatisfactory damage 
Remember that the control simulated ischemia achieved a great level of cardio damage with regards 
to all endpoints evaluated. Specifically for cell viability after I/R, Das and colleagues (2005) reported a 
viability of 60 %, and (2008) 58 %, where PDE5 inhibition could induce protection, compared to the 
12 % cell viability achieved after I/R in Figure 4.5. The 12 % average cell viability indicated that the 
cardiomyocytes underwent harsh injury, to such an extent that PDE5 inhibition could not prevent the 
damage. Cell viability after ischemia was also decreased for the CBD experiments (Figure 4.2), from 
96 % to 29 %, which indicated that the cardiomyocytes were again possibly harmed beyond the ability 
of CBD to induce cardioprotection. 
A low average cell viability after I/R was also found for the morphology selection (Figure 8.5), cell 
viability decreased from 46 % to 8 %. The morphometry measurements increased the average cell 
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viability after I/R significantly compared to the 8 % measured by morphology, where length ≥ 55 μm 
measured 42 % and L/W ≥ 1.5, 51 %. 
The same trend was found for Figure 8.10 and Figure 8.12, where length ≥ 55 μm compared to 
morphology increased cell viability with 50 % and 80 %, respectively. The average cell viability after 
I/R measured by length ≥ 55 μm of 60 % (Figure 8.10) and 65 % (Figure 8.12) were equal to and 
higher than 60 %, which are similar to that reported by Das and colleagues in 2005 and 2008, but the 
cardiomyocytes could still not be protected. 54 % of the cells selected by length ≥ 55 μm were 
55 - 70 μm. Thus, although length ≥ 55 μm could significantly increase the average cell viability 
compared to morphology, the injury induced by ischemia was too harsh and the cells were greatly 
injured. 
The ischemic buffer in Part 1 of this study contained 10 mM SDT and 3 mM 2DG applied for 20 min. 
SDT, Na2S2O4, is an oxygen scavenger and generates superoxide radicals, a reactive oxygen species, 
that causes much greater damage than 2DG, including acidosis, metabolic inhibition and anoxia (Ho 
et al., 2002; Wei et al., 2007). Many studies have used SDT, but in lower concentrations or for a 
shorter period. Examples of these studies are provided below. 
Ischemia with 10 mM SDT and 10 mM 2DG was induced for short periods of 5-min I/10-min R 
(Cao et al., 2005) and 9 or 10-min R (Bian et al., 2005). Trypan blue stain was used for both studies to 
evaluate cell viability by counting the unstained cells as a percentage of the total population. Both 
studies also evaluated cell morphology, where only rod shaped cells (L/W > 3:1) were included in the 
results. Interestingly, according to the average cell viability figure of Cao and colleagues (2005), the 
cell viability for the normoxic controls was low at 55 % and decreased to ± 26 % after I/R, which also 
indicates that the cardiomyocytes were greatly injured. They did not provide the precise statistical 
values. 
Lower concentrations of SDT were used in other simulated ischemia experiments. 
Wei and colleagues (2007) used a model to evaluate myocardial stunning, where they did not want I/R 
to induce contracture/hypercontracture. Here simulated ischemia was for 8 min, with 2 mM SDT with 
10 mM 2DG, pH set at 6.4, followed by 30 min reperfusion (Wei et al., 2007). Trypan blue stain was 
used to evaluate cell viability by counting the unstained cells as a percentage of the total population. 
The researchers found that there was no significant difference between the cell viability for the 
normoxic controls and after I/R, both achieved ± 70 %. 
One study used 2.5 mM SDT, with 20 mM 2DG and 20 mM sodium lactate (used to mimic the 
accumulation of local lactate), pH = 6.5, for 35-min I/10-min R (Hu et al., 2008). Another study used 
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only 0.75 mM SDT, with 10 mM DG and 20 mM lactate for 15 min ischemia, followed by 30 min 
reperfusion (Yu et al., 2008). 
The aim of this study was to induce acute ischemia, but the 10 mM SDT induced severe 
cardiomyocyte injury. The SDT concentration should be much lower, rather between 1 - 3 mM, to 
prevent damaging the cardiomyocytes to the extent that was found in this study. 
Contrary to the harsh injury induced by ischemia, the injury induced by hypoxia was too weak for all of 
the parameters measured (Figure 8.5 – 8.8). Specifically again for cell viability, the morphology 
selection (Figure 8.5) found that hypoxia decreased viability from 46 % to 22 %, where I/R decreased 
the viability to 8 %. With morphometry measurements the cell viability percentage after H/R was 
higher, with 52 % for length ≥ 55 μm, and 70 % for L/W ≥ 1.5, compared to the cell viability measured 
after I/R, 42 % and 51 % respectively. Hypoxia did not induce satisfactory injury compared to the 
normoxic population, only a few cardiomyocytes were damaged and the population seemed to be 
thriving and happy. There is a problem with the ischemia being too harsh, and the hypoxia not 
inducing enough injury. 
Unfortunately, there are other occurring problems, rarely mentioned in the literature, which affects the 
experimental outcome. 
Problems that could affect the experimental outcome  
Variances between the rats 
Individual differences between rats, which can include stress levels, diet and overall health, affects the 
quality of the heart and the cardiomyocytes isolated. The heart of a rat that exhibited stress and 
restlessness before being sacrificed frequently was of a poorer quality than the heart of a calm rat. 
The isolated heart would beat furiously and in most cases the heart had infarcted tissue, or would stop 
beating, before being cannulated and had to be discarded. 
Even if the isolated heart did not show any signs of stress and the isolation protocol was accurately 
followed, the ventricular cardiomyocyte pellet, at the sedimentation step, would suddenly appear 
white, indicating a mass of dead cells. Individual rat heart differences can also be seen during the 
enzyme digestion step, where not one heart takes the same amount of time to digest. 
A critical factor is the weight of the rat. Rats above ~ 260 g are ideal for isolations, because the size of 
the heart and aorta ensures easy dissection and cannulation. The total amount of cardiomyocytes 
isolated from a bigger rat is much higher than from a smaller and younger rat. Differences between 
rats that were included in this study were not an issue. 
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Reliability of isolation 
Producing consistent and reliable isolations are very important. Small human errors during the 
isolation protocol have a great impact on the quality of the isolated cardiomyocytes, which cannot 
always be identified with the eye. These errors can include: not working sterile, cutting the aorta to 
short when dissecting, dropping the isolated heart before it is cannulated, not gassing the isolation 
buffers continuously, forgetting a buffer component, and not accurately following the time period per 
isolation step as stipulated by the protocol.  
Inconsistencies between enzyme batches 
The collagenase, used for digestion, when ordered is delivered in different batch numbers, with batch 
variance. It is important to test the new enzyme batch to determine the efficacy and digestion duration. 
Not testing the collagenase can result in the hearts not digesting properly and the hearts go to waste. 
A poor digested heart also reflects in poor quality cardiomyocytes with low average cell viability after 
isolation and experiments. Yet, high cell viability was achieved 6 years prior when new enzyme 
batches were tested, and it is unlikely that there would be a problem with new batches. Consequently, 
we did not test new collagenase batches, although we should have just to confirm the efficacy of the 
enzyme. Some of the hearts used in this study did not digest completely, but high cell viability was still 
achieved with the cells that could dissociate. 
Quality of cells 
The quality of the isolated cardiomyocytes is determined directly after isolation by evaluating cell 
viability. Cell viability should be above 70 % to yield cardiomyocytes of a high quality, and below 65 % 
is not accepted. However, after the perfusion system went through an acid and water wash, the cell 
viability is usually very low, and only after 4 or 5 hearts are isolated can a high quality be achieved 
again. Cell viability for this study was between 75 – 88 %, which is satisfactory, compared to the 70 % 
(2005) and 85 % (2008) achieved by Das and colleagues. 
Cell viability determined after isolation, after culturing and during I/R 
The quality of the cardiomyocytes is determined directly after isolation by evaluating cell viability. The 
cardiomyocytes are then plated and cultured overnight in the incubator. It is critical that the quality of 
the cardiomyocytes is confirmed under the light microscope the next day before conducting 
experiments. The cardiomyocytes should also be evaluated under the light microscope during an 
experiment, to determine if the period of I/R or H/R was effective. More importantly, cells could wash 
off during an experiment, and evaluating the plate under the microscope throughout the experiment 
can determine when the cells started to wash off. The cultured cardiomyocytes are extremely 
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susceptible to infections, which emphasizes the importance of working sterile. Infected 
cardiomyocytes cannot be used for experiments. Occasionally in our laboratory plates with infected 
cardiomyocytes, after a successful isolation the previous day, had to be thrown away. 
Sensitivity of adhesive 
The L/E, stored at -20 °C, is temperature sensitive and dilution thereof must be done on ice to avoid 
gel formation. If the L/E is not diluted accurately the cardiomyocytes will not adhere, resulting in 
cardiomyocytes simply washing away during the experiment. 
Time of day experiments are done 
The time of day the experiments are conducted could affect the quality of the experimental results, 
where experiments later in the day might results in weaker cells, since the cells are still cultured in the 
same buffer from the previous day. To be consistent, it is important that for a set of experiments each 
experimental day starts at the same time. If experiments will be done later in the day, it might be 
beneficial to, in the morning, remove the buffer the cells were cultured in overnight and to overlay with 
fresh culturing buffer. The experiments in this study were not always conducted at the same time of 
day and might have had an impact on the results. 
The effect of pH change 
The pH of the culturing buffer is set at 7.4 and has a pink alkali colour. Frequently, after overnight 
incubation, when the culturing buffer was removed, the buffer had a yellow colour, which indicates an 
acidic solution. The plates are incubated overnight with 5 % CO2, and it is possible that the CO2 reacts 
with the buffer to decrease the pH. Culturing the cardiomyocytes too long in this acidic buffer could 
induce injury, where the normoxic cells appeared to have undergone I/R. 
Delay between buffer preparation with treatments and administration thereof 
The normoxic wash can be made fresh at the beginning of each experimental week. The 
ischemic/hypoxic buffer, with the supplemented drug treatments, should be made fresh directly before 
ischemia/hypoxia is induced. It is a problem when various different treatments are used in the same 
experiment, which elongates the buffer preparation time. It is not possible to prepare all of the 
treatment buffers at the same time, but it is important to determine which treatments takes preference 
and to prepare them last. Preparing the treatment buffers too early in advance can influence drug 
efficacy and produce misleading experimental results. 
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CONCLUSION 
This study found that 100 μM CBD is cytotoxic, whereas 0.001 μM and 1 μM CBD are tolerated by 
isolated adult rat cardiomyocytes. Cell viability according to morphology found that per-treatment with 
PDE5 inhibitor, or the administration of different CBD concentrations, during ischemia only or 
continuously during ischemia and reperfusion, did not stimulate cardioprotection.  
Length as a morphometry measurement was quantified, where length ≥ 55 μm indicates viable cells in 
a cardiomyocyte population. Morphology selection was proven to be biased and unreliable when 
compared to the morphometry selections, length ≥ 55 μm and L/W ≥ 1.5. With morphometry 
measurements the human aspect is removed and the results are consistent and reliable. 
Length ≥ 55 μm was found to be a more sensitive selection than L/W ≥ 1.5 and can be used to 
evaluate a total cardiomyocyte population. 
The average cell length for the CBD and PDE5 inhibition experiments were evaluated, but 
cardioprotection was not found. Re-evaluating the average cell viability for CBD and PDE5 inhibition 
with length ≥ 55 μm could also not detect any cardioprotection. 
The ischemia induced, for 20 min with 10 mM SDT and for 60 min with 5 mM SDT, was too harsh and 
the cardiomyocytes were injured beyond the ability of the treatments to stimulate protection. In 
contrast, the injury induced by hypoxia compared to the normoxic population was not harsh enough 
and did not induce satisfactory damage. 
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RECOMMENDATIONS 
Simulated ischemia should be induced with a SDT concentration below 10 mM, possibly between 
1 - 3 mM, which needs to be optimized. Hypoxia also needs to be optimized. The experiments should 
be repeated with the new optimized SDT concentration and with the optimized hypoxia. A more 
extensive titration of CBD concentrations between 1 μM and 100 μM should be done to determine the 
optimum concentration that can induce cardioprotection. 
Straight line measurement can be used to measure both the R/G fluorescence and length of a cell to 
evaluate a total cardiomyocyte population. Morphometry analysis, with length ≥ 55 μm as 
measurement, should be used to analyse an injured cardiomyocyte population, and morphology 
analysis should be avoided. 
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